[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2196
1. Frijns CJ, Kasius KM, Algra A, Fijnheer R, Rinkel GJ: Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry; 2006 Jul;77(7):863-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage.
  • BACKGROUND: Endothelial cell activation may be connected with the pathogenesis of delayed cerebral ischaemia (DCI) after subarachnoid haemorrhage (SAH).
  • AIM: To assess the relationship between serial concentrations of circulating markers of endothelial cell activation (soluble intercellular adhesion molecule-1, soluble platelet selectin (sP-selectin), soluble endothelial selectin, ED1-fibronectin, Von Willebrand Factor (VWF) and VWF propeptide) and development of DCI.
  • Changes in levels were analysed in the last sample before and in the first sample after the onset of DCI (n = 30), and in subgroups with DCI occurring within 24 h after treatment of the aneurysm (n = 12) or unrelated to treatment of the aneurysm (n = 18).
  • Patients without DCI (n = 56) served as controls.
  • RESULTS: Concentrations of sP-selectin, but not of the other markers, were found to increase considerably after DCI unrelated to treatment of the aneurysm (increase 25 ng/ml, 95% CI 8 to 43), whereas they tended to decrease in the control patients without DCI (decrease 13 ng/ml, 95% CI -28 to 2.4).
  • Surgery was found to profoundly influence the levels of the markers irrespective of the occurrence of DCI.
  • CONCLUSION: The rise in sP-selectin level during DCI is suggested to be the result of platelet activation, as levels of the other markers of endothelial cell activation were not increased after DCI unrelated to treatment.
  • Whether a causal role of platelet activation is implicated in the development of DCI should be determined in further studies in which the relationship between concentrations of markers and treatment is taken into account.
  • [MeSH-major] Brain Ischemia / etiology. Endothelial Cells / metabolism. Subarachnoid Hemorrhage / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Jun;50(6):1223-9; discussion 1229-30 [12015839.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):329-33 [11511705.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):537-41 [12296636.001]
  • [Cites] Neurosurgery. 2002 Nov;51(5):1128-34; discussion 1134-5 [12383357.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):123-33; discussion 133-5 [12823881.001]
  • [Cites] Stroke. 2003 Sep;34(9):2285-9 [12881605.001]
  • [Cites] Stroke. 2003 Sep;34(9):2132-7 [12907813.001]
  • [Cites] Stroke. 2004 Aug;35(8):1862-6 [15218156.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):985-6 [3131498.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):357-66 [2663879.001]
  • [Cites] Stroke. 1990 Aug;21(8):1156-61 [2389295.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):386-92 [1993903.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3259-87 [8896391.001]
  • [Cites] Neurochem Res. 1997 Oct;22(10):1249-55 [9342729.001]
  • [Cites] Stroke. 1997 Nov;28(11):2214-8 [9368567.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1359-62 [9743222.001]
  • [Cites] Blood. 1999 Jul 1;94(1):179-85 [10381511.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):77-83 [16361599.001]
  • [Cites] Stroke. 1989 Jun;20(6):828 [2728057.001]
  • [Cites] Diabetes Care. 2001 Feb;24(2):323-7 [11213886.001]
  • [Cites] Stroke. 2002 Aug;33(8):2115-22 [12154274.001]
  • (PMID = 16574731.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / P-Selectin
  • [Other-IDs] NLM/ PMC2117487
  •  go-up   go-down


2. Rodríguez García PL, Rodríguez Pupo LR, Rodríguez García D: [Diagnosis of delayed cerebral ischaemia and cerebral vasospasm in subarachnoid haemorrhage]. Neurologia; 2010 Jun;25(5):322-30
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of delayed cerebral ischaemia and cerebral vasospasm in subarachnoid haemorrhage].
  • [Transliterated title] Diagnóstico de la isquemia cerebral tardía y el vasospasmo cerebral en la hemorragia subaracnoidea.
  • OBJECTIVE: A review of current foundations for the medical diagnosis of vasospam and delayed cerebral ischaemia due to spontaneous subarachnoid haemorrhage.
  • DEVELOPMENT: A review of available tests for the investigation of vasospasm (transcraneal Doppler, angiographic methods) and delayed cerebral ischaemia (clinical exam, computerised tomography by X rays, magnetic resonance, emission computerised tomography, electroencephalography, microdialysis) based on type and quality of information, advantages and limitations.
  • Grading and trends for application were also considered for differential diagnosis.
  • CONCLUSIONS: In current clinical practice the most advisable guideline for screening and diagnosis monitoring of vasospasm and delayed cerebral ischaemia is in the first place, based on clinical examination and transcraneal Doppler.
  • Digital subtraction angiography is the current gold standard for diagnosis of cerebral vasospasm.
  • [MeSH-major] Brain Ischemia. Cerebrovascular Circulation / physiology. Subarachnoid Hemorrhage. Vasospasm, Intracranial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurologia. 2011 Jul-Aug;26(6):377-9; author reply 379-81 [21227549.001]
  • (PMID = 20643043.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


3. Rozali A, Khairuddin H, Sherina MS, Zin BM, Sulaiman A: Decompression illness secondary to occupational diving: recommended management based current legistation and practice in Malaysia. Med J Malaysia; 2008 Jun;63(2):166-9
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decompression illness secondary to occupational diving: recommended management based current legistation and practice in Malaysia.
  • Occupational divers are exposed to hazards which contribute to the risk of developing decompression illnesses (DCI).
  • DCI consists of Type I decompression sickness (DCS), Type II DCS and arterial gas embolism (AGE), developed from formation of bubbles in the tissues or circulation as a result of inadequate elimination of inert gas (nitrogen) after a dive.
  • In Malaysia, DCI is one of the significant contributions to mortality and permanent residual morbidity in diving accidents.
  • This is a case of a diver who suffered from Type II DCS with neurological complications due to an occupational diving activity.
  • This article mentions the clinical management of the case and makes several recommendations based on current legislations and practise implemented in Malaysia in order to educate medical and health practitioners on the current management of DCI from the occupational perspective.
  • By following these recommendations, hopefully diving accidents mainly DCI and its sequalae among occupational divers can be minimized and prevented, while divers who become injured receive the proper compensation for their disabilities.
  • [MeSH-major] Accidents, Occupational / legislation & jurisprudence. Decompression Sickness / therapy. Diving / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942312.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


Advertisement
4. Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ: Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology; 2009 Dec;51(12):813-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
  • INTRODUCTION: Vasospasm after aneurysmal subarachnoid hemorrhage (SAH) is thought to cause ischemia.
  • To evaluate the contribution of vasospasm to delayed cerebral ischemia (DCI), we investigated the effect of vasospasm on cerebral perfusion and the relationship of vasospasm with DCI.
  • CTP values (cerebral blood volume, cerebral blood flow (CBF) and mean transit time), degree of vasospasm on CTA, and occurrence of DCI were recorded.
  • The correspondence of the flow territory of the most spastic vessel with the least perfused region was evaluated, and differences in perfusion values and occurrence of DCI between degrees of vasospasm were calculated with 95% confidence intervals (95% CI).
  • Four of seven patients with severe, six of 16 with moderate, and three of 14 patients with no vasospasm had DCI.
  • CONCLUSION: Vasospasm decreases cerebral perfusion, but corresponds with the least perfused region in only two thirds of our patients.
  • Furthermore, almost half of patients with severe vasospasm do not have DCI.
  • Thus, although severe vasospasm can decrease perfusion, it may not result in DCI.
  • [MeSH-major] Brain Ischemia / diagnosis. Brain Ischemia / etiology. Cerebral Angiography / methods. Cerebrovascular Circulation. Subarachnoid Hemorrhage / complications. Subarachnoid Hemorrhage / diagnosis. Vasospasm, Intracranial / diagnosis. Vasospasm, Intracranial / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2000 Mar;28(3):824-9 [10752836.001]
  • [Cites] Neuroradiology. 2009 Feb;51(2):85-93 [18850093.001]
  • [Cites] Neurosurgery. 2001 Sep;49(3):622-6; discussion 626-7 [11523672.001]
  • [Cites] Stroke. 2004 Aug;35(8):1862-6 [15218156.001]
  • [Cites] Invest Radiol. 1983 Jan-Feb;18(1):94-9 [6832937.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):48-58 [3964855.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):985-6 [3131498.001]
  • [Cites] Acta Neurochir (Wien). 1988;93(3-4):123-8 [3177027.001]
  • [Cites] Ann Biomed Eng. 1999 Mar-Apr;27(2):257-73 [10199702.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):633-54; discussion 633-54 [15792502.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):26-34 [16418351.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):370-7 [16484413.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):319-25; discussion 319-25 [16883171.001]
  • [Cites] Neurosurg Focus. 2006;21(3):E2 [17029341.001]
  • [Cites] Neurosurg Focus. 2006;21(3):E8 [17029347.001]
  • [Cites] J Physiol Pharmacol. 2006 Nov;57 Suppl 11:145-60 [17244946.001]
  • [Cites] Lancet. 2007 Jan 27;369(9558):306-18 [17258671.001]
  • [Cites] Stroke. 2007 Mar;38(3):981-6 [17272764.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Apr;28(4):750-8 [17416833.001]
  • [Cites] Stroke. 2007 Jun;38(6):1831-6 [17446425.001]
  • [Cites] Neurology. 2007 Aug 21;69(8):762-5 [17709708.001]
  • [Cites] Neuroradiology. 2008 Jan;50(1):1-8 [17922121.001]
  • [Cites] Cerebrovasc Dis. 2008;25(1-2):144-50 [18073468.001]
  • [Cites] Cerebrovasc Dis. 2008;26(2):163-70 [18560220.001]
  • [Cites] Neuroradiology. 2008 Sep;50(9):813-20 [18548240.001]
  • [Cites] Neuroradiology. 2008 Nov;50(11):929-38 [18560816.001]
  • [Cites] J Neuroimaging. 2008 Oct;18(4):396-401 [18494776.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):905-14 [11337336.001]
  • (PMID = 19623472.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2773037
  •  go-up   go-down


5. Ductal breast cancer not related to women's intake of alcohol. Nurs Stand; 2010 Oct 06;25(5):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal breast cancer not related to women's intake of alcohol.
  • : Alcohol consumption is not associated with the risk of ductal carcinoma in situ, according to the findings of a large study of postmenopausal women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28041269.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Hurford DM, White MC: A comparison of the Glidescope and Karl Storz DCI videolaryngoscopes in a paediatric manikin. Anaesthesia; 2010 Aug;65(8):781-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of the Glidescope and Karl Storz DCI videolaryngoscopes in a paediatric manikin.
  • This varies in design from the Karl Storz DCI videolaryngoscope, as it possesses a short curved disposable blade compared with the narrower straighter blade of the Storz.
  • We compared the time taken for tracheal intubation under normal and difficult intubation conditions in a paediatric manikin.
  • A total of 32 anaesthetists completed four intubations in a random order, with each participant blinded to the airway condition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528838.001).
  • [ISSN] 1365-2044
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ: Achieved serum magnesium concentrations and occurrence of delayed cerebral ischaemia and poor outcome in aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry; 2007 Jul;78(7):729-31
Hazardous Substances Data Bank. MAGNESIUM SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achieved serum magnesium concentrations and occurrence of delayed cerebral ischaemia and poor outcome in aneurysmal subarachnoid haemorrhage.
  • BACKGROUND: Magnesium therapy probably reduces the frequency of delayed cerebral ischaemia (DCI) in subarachnoid haemorrhage (SAH) but uncertainty remains about the optimal serum magnesium concentration.
  • We assessed the relationship between serum magnesium concentrations achieved with magnesium sulphate therapy 64 mmol/day and the occurrence of DCI and poor outcome in patients with SAH.
  • METHODS: Differences in magnesium concentrations between patients with and without DCI and with and without poor outcome were calculated.
  • Quartiles of last serum magnesium concentrations before the onset of DCI, or before the median day of DCI in patients without DCI, were related to the occurrence of DCI and poor outcome at 3 months using logistic regression.
  • RESULTS: Compared with the lowest quartile of serum magnesium concentration (1.10-1.28 mmol/l), the risk of DCI was decreased in each of the higher three quartiles (adjusted odds ratio (OR) in each quartile 0.2; lower 95% CI 0.0 to 0.1; upper limit 0.8 to 0.9).
  • DISCUSSION: Magnesium sulphate 64 mmol/day results in a stable risk reduction of DCI over a broad range of achieved serum magnesium concentrations, and strict titration of the dosage therefore does not seem necessary.
  • However, concentrations < or = 1.28 mmol/l could decrease the effect on DCI while concentrations > or = 1.62 might have a negative effect on clinical outcome.
  • [MeSH-major] Brain Ischemia / etiology. Brain Ischemia / prevention & control. Intracranial Aneurysm / complications. Intracranial Aneurysm / drug therapy. Magnesium / blood. Magnesium Sulfate / therapeutic use. Subarachnoid Hemorrhage / complications. Subarachnoid Hemorrhage / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):337-41 [10675216.001]
  • [Cites] J Neurol. 2006 Sep;253(9):1217-20 [16998645.001]
  • [Cites] Clin Pharmacokinet. 2000 Apr;38(4):305-14 [10803454.001]
  • [Cites] Neurology. 2000 Dec 12;55(11):1656-60 [11113219.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1877-90 [12057549.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):276-81; discussion 281-2 [12535355.001]
  • [Cites] Hypertens Pregnancy. 2003;22(3):257-65 [14572362.001]
  • [Cites] Stroke. 1988 May;19(5):604-7 [3363593.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):985-6 [3131498.001]
  • [Cites] Stroke. 1990 Aug;21(8):1156-61 [2389295.001]
  • [Cites] Am J Med. 1994 Jan;96(1):63-76 [8304365.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):117-24 [8683260.001]
  • [Cites] J Emerg Med. 1996 Mar-Apr;14(2):187-91 [8740750.001]
  • [Cites] Stroke. 1997 Mar;28(3):660-4 [9056628.001]
  • [Cites] Stroke. 1998 May;29(5):918-23 [9596235.001]
  • [Cites] Clin Obstet Gynecol. 2005 Jun;48(2):478-88 [15805803.001]
  • [Cites] Stroke. 2005 May;36(5):1011-5 [15790946.001]
  • [Cites] J Clin Pharm Ther. 2005 Oct;30(5):439-42 [16164489.001]
  • [Cites] Stroke. 2006 Jun;37(6):e27-35 [16731862.001]
  • [Cites] Neurosci Lett. 2000 May 12;285(2):119-22 [10793241.001]
  • (PMID = 17135457.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7487-88-9 / Magnesium Sulfate; I38ZP9992A / Magnesium
  • [Other-IDs] NLM/ PMC2117699
  •  go-up   go-down


8. Dankbaar JW, de Rooij NK, Rijsdijk M, Velthuis BK, Frijns CJ, Rinkel GJ, van der Schaaf IC: Diagnostic threshold values of cerebral perfusion measured with computed tomography for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke; 2010 Sep;41(9):1927-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic threshold values of cerebral perfusion measured with computed tomography for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
  • BACKGROUND AND PURPOSE: Early diagnosis of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage is critical but difficult.
  • We analyzed diagnostic threshold values of CT perfusion for use in detection of DCI in patients with subarachnoid hemorrhage.
  • The gold standard was the clinical diagnosis of DCI based on all clinical, laboratory, and imaging data except CT perfusion.
  • We measured CT perfusion values, including cerebral blood volume, blood flow, mean transit time (MTT), and time to peak in predefined regions of interest and then compared absolute perfusion and perfusion asymmetry for patients with and without DCI.
  • Diagnostic threshold values for DCI were evaluated and sensitivity and specificity calculated for optimal thresholds.
  • RESULTS: Of 85 eligible patients with subarachnoid hemorrhage, 50 had DCI; 35 patients with no clinical deterioration comprised the reference group.
  • Cerebral blood flow was significantly lower, MTT higher, and perfusion asymmetry larger in patients with DCI.
  • CONCLUSIONS: Thresholds for absolute MTT values and between-hemisphere MTT differences on CT perfusion can distinguish between patients with delayed cerebral ischemia and clinically stable patients.
  • [MeSH-major] Brain / radiography. Brain Ischemia / radiography. Cerebrovascular Circulation / physiology. Subarachnoid Hemorrhage / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Delayed Diagnosis. Female. Hemodynamics. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20689085.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Vann RD, Denoble PJ, Howle LE, Weber PW, Freiberger JJ, Pieper CF: Resolution and severity in decompression illness. Aviat Space Environ Med; 2009 May;80(5):466-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution and severity in decompression illness.
  • omegaWe review the terminology of decompression illness (DCI), investigations of residual symptoms of decompression sickness (DCS), and application of survival analysis for investigating DCI severity and resolution.
  • The method applies to a continuum of resolution times, allows for time varying information, can manage cases lost to follow-up (censored), and has potential for investigating questions such as optimal therapy and DCI severity.
  • Appropriate definitions of mild and serious manifestations are essential for computing probabilistic decompression procedures where severity determines the DCS probability that is acceptable.
  • Application of survival analysis to DCI data would require more specific case information than is commonly recorded.
  • [MeSH-major] Decompression Sickness / diagnosis. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456008.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


10. Togawa S, Maruyama M, Yamami N, Nakayama H, Shibayama M, Kawashima M, Shimada K, Mano Y: Dissociation of neurological deficits in spinal decompression illness. Undersea Hyperb Med; 2006 Jul-Aug;33(4):265-70
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation of neurological deficits in spinal decompression illness.
  • This study examined 103 spinal decompression illness (DCI) cases.
  • We concluded that clinical neurological deficit dissociation is frequently observed in spinal DCI.
  • [MeSH-major] Decompression Sickness / physiopathology. Hypesthesia / physiopathology. Motor Neuron Disease / physiopathology. Spinal Cord Diseases / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004413.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bennett MH, Lehm JP, Mitchell SJ, Wasiak J: Recompression and adjunctive therapy for decompression illness. Cochrane Database Syst Rev; 2007;(2):CD005277
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recompression and adjunctive therapy for decompression illness.
  • BACKGROUND: Decompression illness (DCI) is due to bubble formation in the blood or tissues following the breathing of compressed gas.
  • Clinically, DCI may range from a trivial illness to loss of consciousness, death or paralysis.
  • Recompression is the universally accepted standard for the treatment of DCI.
  • When recompression is delayed, a number of strategies have been suggested in order to improve the outcome.
  • OBJECTIVES: To examine the effectiveness and safety of both recompression and adjunctive therapies in the treatment of DCI.
  • In one study there was no evidence of improved effectiveness with the addition of a non-steroidal anti-inflammatory drug (tenoxicam) to routine recompression therapy (at six weeks: relative risk (RR) 1.04, 95% confidence interval (CI) 0.90 to 1.20, P = 0.58) but there was a reduction in the number of compressions required when tenoxicam was added (P = 0.01, 95% CI 0 to 1).
  • AUTHORS' CONCLUSIONS: Recompression therapy is standard for the treatment of DCI, but there is no randomized controlled trial evidence.
  • [MeSH-major] Decompression Sickness / therapy. Hyperbaric Oxygenation / methods
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Humans. Piroxicam / analogs & derivatives. Piroxicam / therapeutic use. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;5:CD005277 [22592704.001]
  • (PMID = 17443579.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; 59804-37-4 / tenoxicam
  • [Number-of-references] 44
  •  go-up   go-down


12. Trevett AJ, Sheehan C, Forbes R: Decompression illness presenting as breast pain. Undersea Hyperb Med; 2006 Mar-Apr;33(2):77-9
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decompression illness presenting as breast pain.
  • We present two cases of decompression illness in women in whom the initial symptom causing distress after completion of the dives was breast pain.
  • We postulate that breast pain may be an unusual under-recognized manifestation of decompression illness.
  • [MeSH-major] Breast Diseases / etiology. Decompression Sickness / complications. Pain / etiology
  • [MeSH-minor] Adult. Decompression. Exanthema / etiology. Female. Heart Septal Defects, Atrial / complications. Humans. Pain Management

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716055.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab; 2008 Nov;28(11):1761-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia.
  • Patients with aneurysmal subarachnoid hemorrhage (SAH) who experience delayed cerebral ischemia (DCI) have an increased risk of poor outcome.
  • Delayed cerebral ischemia is considered to be caused by vasospasm.
  • However, not all patients with DCI have vasospasm.
  • Inversely, not all patients with vasospasm develop clinical symptoms and signs of DCI.
  • In the past, treatments aiming at vasospasm were not successful in preventing ischemia.
  • The purpose of this review is to give an overview of clinical data showing that DCI cannot always be attributed to vasospasm, and to present an in-depth analysis of clinical and autopsy studies on the role of microthrombosis in the pathogenesis of DCI.
  • Clinical studies show that DCI is associated with an activation of the coagulation cascade within a few days after SAH, preceding the time window during which vasospasm occurs.
  • Furthermore, impaired fibrinolytic activity, and inflammatory and endothelium-related processes, lead to the formation of microthrombi, which ultimately result in DCI.
  • Insight in the pathophysiology of DCI is crucial for the development of effective therapies against this complication.
  • [MeSH-major] Brain Ischemia / etiology. Coronary Thrombosis / etiology. Subarachnoid Hemorrhage / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628782.001).
  • [ISSN] 1559-7016
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


14. Tunon de Lara C: [Ductal carcinoma in situ of the breast (DCIS) under 40: a specific management?]. Gynecol Obstet Fertil; 2008 May;36(5):499-506
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal carcinoma in situ of the breast (DCIS) under 40: a specific management?].
  • [Transliterated title] Carcinome canalaire in situ (CCIS) chez les femmes de moins de 40 ans: une prise en charge particulière?
  • Ductal carcinoma in situ of the breast (DCIS) is rare in younger women, accounting for about 4% of all cases of DCIS in France, and tends to be diagnosed by clinical findings or casually, after plastic surgery.
  • After breast conserving treatment, young age ( less than 40) is a predictive factor of relapses in patients with DCIS.
  • Age may serve as one more parameter that should be considered in the complex decision-making process necessary to create a treatment plan for a woman with DCIS.
  • Breast conservative treatment (BCT) could be used if: margins are free and more than 10 mm; if DCIS size is less than 11 mm and DCIS is free of necrosis and comedocarcinoma.
  • Mastectomy ought to be proposed in case of: multifocal DCIS, or DCIS size more than 30 mm; invaded margins after re-excision; radiotherapy contraindicated; small breasts and patient choice.
  • Immediate breast reconstruction should be proposed for patients with all the poor predictive factors.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy / methods
  • [MeSH-minor] Adult. Age Factors. Combined Modality Therapy. Female. Humans. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Obstet Fertil. 2008 Jun;36(6):704; author reply 704-5 [18539508.001]
  • [CommentIn] Gynecol Obstet Fertil. 2008 Jun;36(6):705-6 [18539513.001]
  • (PMID = 18467151.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 70
  •  go-up   go-down


15. Carrera E, Schmidt JM, Oddo M, Fernandez L, Claassen J, Seder D, Lee K, Badjatia N, Connolly ES Jr, Mayer SA: Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Neurosurgery; 2009 Aug;65(2):316-23; discussion 323-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage.
  • OBJECTIVE: Transcranial Doppler (TCD) is widely used to monitor the temporal course of vasospasm after subarachnoid hemorrhage (SAH), but its ability to predict clinical deterioration or infarction from delayed cerebral ischemia (DCI) remains controversial.
  • The highest mean blood flow velocity (mBFV) value in any vessel before DCI onset was recorded.
  • DCI was defined as clinical deterioration or computed tomographic evidence of infarction caused by vasospasm, with adjudication by consensus of the study team.
  • Logistic regression was used to calculate adjusted odds ratios for DCI risk after controlling for other risk factors.
  • RESULTS: DCI occurred in 21% of patients (n = 92).
  • Multivariate predictors of DCI included modified Fisher computed tomographic score (P = 0.001), poor clinical grade (P = 0.04), and female sex (P = 0.008).
  • After controlling for these variables, all TCD mBFV thresholds between 120 and 180 cm/s added a modest degree of incremental predictive value for DCI at nearly all time points, with maximal sensitivity by SAH day 8.
  • However, the sensitivity of any mBFV more than 120 cm/s for subsequent DCI was only 63%, with a positive predictive value of 22% among patients with Hunt and Hess grades I to III and 36% in patients with Hunt and Hess grades IV and V.
  • CONCLUSION: Increased TCD flow velocities imply only a mild incremental risk of DCI after SAH, with maximal sensitivity by day 8.
  • Nearly 40% of patients with DCI never attained an mBFV more than 120 cm/s during the course of monitoring.
  • Given the poor overall sensitivity of TCD, improved methods for identifying patients at high risk for DCI after SAH are needed.
  • [MeSH-major] Brain Ischemia / ultrasonography. Cerebral Arteries / ultrasonography. Subarachnoid Hemorrhage / complications. Ultrasonography, Doppler, Transcranial / methods. Vasospasm, Intracranial / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2010 Oct;67(4):E1180 [20925141.001]
  • [CommentIn] Neurosurgery. 2011 Aug;69(2):E501-2 [21499158.001]
  • (PMID = 19625911.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Newton HB, Padilla W, Burkart J, Pearl DK: Neurological manifestations of decompression illness in recreational divers - the Cozumel experience. Undersea Hyperb Med; 2007 Sep-Oct;34(5):349-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological manifestations of decompression illness in recreational divers - the Cozumel experience.
  • Neurological signs and symptoms are common in recreational divers with decompression illness (DCI).
  • The spectrum of neurological manifestations, temporal profile, and laboratory findings are described in a large series of 200 consecutive recreational divers treated for DCI.
  • The Hyperbaric Medicine Unit charts of 200 recreational divers treated for DCI were reviewed and analyzed.
  • One hundred seventy-seven of 200 divers (88.5%) had at least one symptom of neurological DCI at presentation.
  • Neurological manifestations are common in recreational divers treated for DCI.
  • Neurological DCI and paresthesias are more likely to occur in younger and less experienced divers.
  • [MeSH-major] Decompression Sickness / complications. Diving / adverse effects. Nervous System Diseases / etiology

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019086.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Peacock N, Saleh M, Bendell J, Rose AA, Dong Z, Siegel PM, Crowley E, Simantov R, Vahdat L: A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC).
  • : 1067 Background: Glycoprotein NMB (GPNMB), also known as osteoactivin, has been shown to regulate metastasis of breast cancer in vivo.
  • This is the first study of CR011-vcMMAE in breast cancer.
  • Immunohistochemistry (IHC) with goat polyclonal antibody to GPNMB was performed on pt biopsy specimens and on tissue microarrays containing normal breast, DCIS, breast tumor and lymph node metastases.
  • RESULTS: 10 pts with MBC (median age 57, range 36 - 69) had a median of 7 prior regimens and were treated with CR011-vcMMAE for a median of 2 cycles (range 1-4).
  • A response of 37% tumor shrinkage was seen in a pt after only 2 cycles and is ongoing.
  • Breast tumor samples were more likely to stain positive for GPNMB than normal breast tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961164.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ozmen V, Ozkan Gurdal S, Muslumanoglu M, Igci A, Tuzlali SS, Ozcinar B, Canbay E, Kecer M, Dagoglu T: Predictive factor for residual tumor after lumpectomy for close margins. J Clin Oncol; 2009 May 20;27(15_suppl):e11538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e11538 Background: It is critical to obtain clear margins to minimize local recurrence after breast conserving surgery(BCS).
  • When re-excisions are performed, there is often no residual disease in the new specimen, calling into question the need for re-excision(s) or mastectomy.
  • METHODS: Our prospective breast cancer database was queried for all invasive breast cancer patients who underwent a re-excision lumpectomy for either close or positive margins after an attempt at BCS.
  • Close margins are defined as ≤ 2 mm for invasive carcinoma and presence of ductal carcinoma in situ(DCIS).
  • Clinicopathologic features were correlated with the presence of residual disease in the re-excision specimen.
  • RESULTS: Between February 1997 and August 2008, 2054 patients with early breast cancer underwent surgical treatment in our breast unit.
  • The factors associated with tumor positive re-excision specimen were, age ≤50 years(p=0.044), lymphovascular invasion (p=0.029), multifocality(p<0.001), tumor size >2cm(p=0.008), presence of DCIS(p=0.018), focal margin positivity(p<0.001), DCIS at resection margin(p=0.008) and node positivity (p<0.001).
  • CONCLUSIONS: Most of our patients with early breast cancer had unnecessary re-excisions or mastectomy to obtain clear surgical margins.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964684.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA: Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC). J Clin Oncol; 2009 May 20;27(15_suppl):e11528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC).
  • : e11528 Background: ILC is characterized by a diffusely infiltrative growth pattern making it difficult to accurately assess disease extent prior to surgical resection.
  • This has resulted in difficulty obtaining negative margins at the time of breast conserving surgery.
  • Pathologic data included margin status (negative (>2mm), close (0-2mm), or positive), multifocality, multicentricity, ILC subtype, grade, associated LCIS or DCIS, hormone receptor status and HER2 status.
  • Patients with close or positive margins were more likely to have distortion on ultrasound (vs. mass, p=.05), to have undergone an excisional biopsy (vs. core or FNA, p=.008), and to have associated DCIS (p=.02).
  • Having an excisional biopsy for diagnosis was also associated with need for multiple surgeries (p < .0001).
  • Breast conserving surgery was ultimately successful in 86 patients (85%).
  • CONCLUSIONS: The majority of patients with ILC can undergo successful breast conserving surgery.
  • Patients with distortion rather than a mass on imaging and those with DCIS are more likely to have close or positive margins.
  • Diagnosis by excisional biopsy makes subsequent imaging less reliable and results in the need for multiple surgeries to ensure adequate excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gronwald J, Byrski T, Huzarski T, Dent R, Bielicka V, Zuziak D, Wisniowski R, Lubinski J, Narod S: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
  • : 502 Background: Neoadjuvant chemotherapy is administered to control disease, make surgical resection possible and increase the possibility of breast tissue conservation.
  • Induction of a pathological complete response (pCR) is one of the primary goals of neoadjuvant therapy in order to achieve a better disease-free and overall survival.
  • Experimental data suggest that BRCA1 related breast cancer may have increased sensitivity to platinum-based chemotherapy, but clinical data are limited.
  • The aim of this study was to evaluate the frequency of complete pathologic response after neo-adjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation.
  • METHODS: Twenty five women with breast cancer and a BRCA1 mutation with stage I, II, and III breast cancer between December 2006 and December 2008 were entered into this study.
  • After chemotherapy, patients underwent surgery and were assessed for pathologic response in both the breast and axillary lymph nodes.
  • Complete pathologic response was defined as no residual invasive disease in both the breast and axilla, however ductal carcinoma in situ was allowed.
  • Thirteen patients had tumors of greater than two centimeters (52%) and seven patients had positive lymph nodes at diagnosis (28%).
  • CONCLUSIONS: Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancers.
  • Clinical trials are warranted to determine the optimum treatment for this subgroup of breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Sircar T, Chaudhri S, Francis A: Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer.
  • : e11588 Background: Neoadjuvant chemotherapy(NC) is used in treating locally advanced operable breast cancer.
  • METHODS: This is a retrospective study of 32 patients with locally advanced breast cancer who had NC followed by breast conservation surgery or mastectomy.
  • RESULTS: After NC, 5 patients had complete pathological response and 2 patients had residual ductal carcinoma in situ.
  • 25(78%) patients had residual invasive malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964117.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ismael G, Coradazzi AL, Beato CA, Milhomem P, Oliveira J, Manzoni C, Segalla G: Adjuvant systemic therapy in elderly patients with breast cancer: A Brazilian single center experience. J Clin Oncol; 2009 May 20;27(15_suppl):e20711

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic therapy in elderly patients with breast cancer: A Brazilian single center experience.
  • : e20711 Background: Breast cancer is the leading cause of cancer in women in Brazil and in the western world.
  • Despite the high incidence of breast cancer in elderly women, there is no solid information regarding the real impact of the adjuvant systemic therapy in this population, considering the underrepresentation of patients with 65 years of age or older in cancer-treatment trials.
  • METHODS: Two hundred fifty eight patients with 65 years of age or older at the time of diagnosis of operable breast cancer and treated in our Institution from February 2000 to December 2005 were retrospectively studied.
  • We evaluated the disease free survival and overall survival and compared the results between the group of patients treated with HT only and the group of patients treated with both HT and CT.
  • RESULTS: Ninety five (37.5%) patients were stage I, 150 (58.1%) were stage II and 6 (2.3%) were stage III, while 5 (1.9%) patients were diagnosed with DCIS.
  • Ductal carcinoma was the most frequent histological type (81%) and grade II were reported in the majority of patients (47.3%).
  • There was no statistical difference between patients treated with HT when compared with the group of patients treat with HT and CT, regarding disease free survival and overall survival.
  • CONCLUSIONS: Despite the age, a considerable part of this elderly breast cancer patient's population has received adjuvant systemic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Schmitz AC, van den Bosch MA, Loo C, Peterse JL, Gertenbach M, Mali WP, Rutgers EJ, Gilhuijs KG: Visualization of invasive breast cancer and its subclinical disease spread within the breast: Precise correlation between MR imaging findings and histopathologic findings. J Clin Oncol; 2009 May 20;27(15_suppl):610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of invasive breast cancer and its subclinical disease spread within the breast: Precise correlation between MR imaging findings and histopathologic findings.
  • : 610 Background: Magnetic Resonance Imaging (MRI) of the breast shows superior ability to visualize the extent of invasive breast cancer compared to conventional breast imaging.
  • Nonetheless, MRI may under- or overestimate the extent of invasive disease, and the ability of MRI to depict components of disease around the primary invasive tumor is not well established.
  • The purpose of this study was to precisely correlate MRI findings with histopathologic findings in breast cancer patients and to establish the incidence and quantity of surrounding MRI occult disease in breast cancer patients that are scheduled for breast-conserving therapy (BCT).
  • METHODS: Patients were prospectively included if they had biopsy-proven invasive breast cancer and the choice of treatment was BCT after pre-operative MRI.
  • Tumors were stratified by absence or presence of an extensive intraductal component (EIC- or EIC+).
  • The largest diameter of the MRI-visible lesion was compared with the largest diameter of the primary invasive tumor at pathology.
  • Distances (mm) between the edge of the MRI-visible lesion and surrounding subclinical tumor foci (i.e., DCIS, invasive foci) were measured.
  • At various distances from the edge of the MRI-visible tumor, the incidence of disease was determined.
  • RESULTS: 53 patients with 54 breast tumors were included.
  • The mean size (± SD) of the primary invasive tumor was 18.1 ± 7.5 mm on MRI and 19.5 ± 8.2 mm on pathology (Pearson's correlation coefficient: 0.75).
  • The MRI-visible lesion was larger than or equal to the primary invasive tumor on pathology in 21 (39%) cases.
  • Underestimation of the primary invasive tumor occurred up to 7 mm from the edge of the MRI-visible lesion.
  • CONCLUSIONS: Disease around MRI-visible lesions may be more extensive than assumed prior to treatment, especially in EIC+ tumors.
  • This may have consequences for treatment margins in MRI-guided therapy of localized breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961480.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Shi Y, Zhang F, Cao M, Zhang Y, Xu Y, Huang M, Wang H, Ma Y: The role of EGFR MAbs C225 in breast cancer stem cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of EGFR MAbs C225 in breast cancer stem cells.
  • : e22093 Background: The epithermal growth factor receptor(EGFR) signaling pathways has been implicated in self-renewal of breast cancer stem cells.
  • It has been proved that the EGFR tyrosine kinase inhibitor-gefitinib significantly decreased the mammosphere- forming efficiency(MFE) in ductal carcinoma in situ (DCIS) derived cancer cells.
  • We investigated the response of breast cancer stem cells in breast cancer cell line MCF-7 to EGFR MAbs C225(cetuximab).
  • The expression of Notch-3 is increased with the EGFR antagonistics in breast cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963278.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in breast cancer: technique and indication.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • SNB in breast cancer was accepted as a sole and reliable diagnostic method in breast cancer by the panel of distinguished experts at the 8th international conference of primary therapy of early breast cancer 2003 in St. Gallen.
  • Accepted indications are uni- and multifocal tumors smaller than 3 cm without suspicious findings in the axilla, furthermore SNB is indicated in patients with large ductal carcinoma in situ (>2 cm) and/or with assumed microinvasion.
  • Albeit SNB could be shown to be safe after preoperative chemotherapy and in multicentric breast cancer, due to lack of sufficient data it is still under discussion in these cases.
  • Application of serial sectioning and immunohistochemistry results in a more accurate staging than routine examination.
  • Although many unicentric and multicentric observational studies validated by complete axillary dissection could demonstrate that SNB is accurate and suitable for all operable clinically node-negative breast cancers, long-term results and especially the incidence of axillary recurrence and its sequelae are outstanding.
  • Findings of ongoing large prospective randomized trials like NSABP 32, Z0010 and Z0011 of the American College of Surgeons (ACOSOG), the AMAROS-Trial of the European Organisation of Research and Treatment of Cancer (EORTC) and the ALMANAC-Trial of the British Association of Surgical Oncology (BASO) will give a conclusive answer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


26. Zidan J, Geslikov M: Clinical and pathological features of breast cancer in Arab compared to Jewish women in Northern Israel. J Clin Oncol; 2009 May 20;27(15_suppl):e22201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological features of breast cancer in Arab compared to Jewish women in Northern Israel.
  • : e22201 Background: Breast cancer (BC) is the most common malignancy in both Jewish and Arab women in Israel.
  • Molecular features are increasingly used for predicting cancer prognosis and response to treatment.
  • The purpose of this study to compare clinical, pathological and molecular characteristics of BC in Arab and Jewish women in the Upper Galilee Methods: The files of 481 patients (pts) with breast cancer (BC) treated at the Oncology Institute, Ziv Medical Center between 2001 and 2007 were reviewed retrospectively.
  • Type of breast operation and both clinical and all pathological findings of patients were summarized and correlated to the ethnicity of women.
  • The main age at diagnosis was 49,4 years for Arabs and 59,5 years for Jews (p<0,01).
  • At diagnosis 3% of Arab pts had DCIS compared to 7,4% in Jewish pts, stage I in 19% and 49,9%, stage II in 36% and 31,7%, stage III in 33,3% and 7,6%, stage IV in 9% and 3,7% of Arab and Jewish pts respectively (p<0,05).
  • CONCLUSIONS: Our data demonstrate younger age and more advanced tumor at diagnosis in Arab compared to Jewish women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH: Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol; 2009 May 20;27(15_suppl):517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study.
  • : 517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas.
  • There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • METHODS: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded.
  • With a 25 months median follow-up, there was no invasive recurrence in TZM treated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Masuda N, Ando M, Aogi K, Ino H, Iwata H, Tokuda Y, Nakamura S, Yamamoto N, Fujiwara Y: Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2. J Clin Oncol; 2009 May 20;27(15_suppl):565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2.
  • : 565 Background: Achievement of pathological complete response (pCR) by primary systemic therapy (PST) correlates with improved survival in operable breast cancer patients.
  • The primary objective was designed to evaluate the pCR, defined as no evidence of residual invasive cancer in axilla and breast.
  • Out of 30 pts with pCR, 13 pts had component of DCIS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Blakely L, Somer B, Keaton M, Hermann R, Schnell F, Cobb P, Johns A, Walker M, Schwartzberg L: Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer.
  • : 595 Background: Neoadjuvant (Neo) chemotherapy (CT) with trastuzumab (H) improves pathologic complete response (pCR) rate for HER2+ breast cancer.
  • We designed this regimen to utilize full doses of active agents including docetaxel (T) and H in a novel biweekly schedule to explore efficacy and safety.
  • METHODS: Patients (pts) with biopsy proven, clinical stage IIA-IIIC, noninflammatory breast cancer were eligible.
  • The primary endpoint was pCR for invasive cancer in breast and lymph nodes.
  • Pathologic response: pCR 16 (57%) including 4 with residual DCIS only; 9 pPR, and 2 stable.
  • CONCLUSIONS: Sequential Neo dose-dense Q 14 day EC followed by Q 14 day TH yields a high pCR rate in HER2+ breast cancer with acceptable toxicity profile and no new safety signals noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Alabdulkarim YA, Nassif E: Isolated tumor cells versus micro-metastasis in sentinel lymph node biopsy for T1, T2 breast cancer compared to macro-metastasis: Significance after complete axillary dissection. J Clin Oncol; 2009 May 20;27(15_suppl):e12028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated tumor cells versus micro-metastasis in sentinel lymph node biopsy for T1, T2 breast cancer compared to macro-metastasis: Significance after complete axillary dissection.
  • : e12028 Background: Evaluating the axillary lymph nodes is extremely important in the management of breast cancer, with the recent improvement in histopathology techniques detection of micro-metastasis and even isolated cancer cells (ITC) in a setting of sentinel lymph node examination is feasible.
  • METHODS: We reviewed all the patients who had SLN for breast cancer of stage T 1-2 between April 2006 and November 2008.
  • Identifying all those who had positive macro-metastasis, micro-metastasis, or isolated tumor cells, pathology results of the full axillary LN dissection was evaluated for each type.
  • RESULTS: 350 patients had SLN of these 226 had a disease of T1-2, thirty seven patients (16.3%) had full axillary dissection, of these 27/37 had positive SLN for macro-metastasis, six had micro-metastasis and 3/37 had only ITCs.
  • The presence of other LN metastasis was detected in 8 cases (21.6%); all of them were in the macro-metastasis group.
  • The ITC was only detected with DCIS; while micro-metastasis was present in DCIS or IDC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964304.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bernard JR Jr, Vallow LA, McNeil RB, McLaughlin SA, Geiger XJ, Perez EA: In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI? J Clin Oncol; 2009 May 20;27(15_suppl):627

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI?
  • We evaluated whether a negative contralateral MRI could be used to rule out a synchronous contralateral carcinoma and hence avoid a prophylactic contralateral mastectomy (CPM) at initial breast cancer diagnosis.
  • METHODS: Data of women with a new diagnosis of breast cancer (invasive or DCIS) from February 2003-November 2007 at our institution were reviewed.
  • Women who had a negative MRI of the contralateral breast and who subsequently underwent CPM were included.
  • A CPM was one in which there was no histological confirmation of cancer in the contralateral breast before surgery.
  • True negatives were mastectomy samples which contained no cancer following pathologic examination.
  • False negatives were mastectomy samples which were found to have cancer after pathologic review.
  • Of the 51 women who underwent a CPM, 2 were found to have pathologic confirmation of cancer.
  • One occult cancer was a 0.3 cm grade 1, invasive lobular carcinoma; the second a 0.5 cm, low grade DCIS.
  • The overall prevalence of synchronous occult contralateral cancer after a negative MRI was 3.9% (95% CI 0.5 - 13.5%).
  • CONCLUSIONS: This study provides pathologic data regarding the utility of a negative contralateral breast MRI in women with newly diagnosed breast cancer.
  • The prevalence of a synchronous occult contralateral cancer after a negative MRI in women with newly diagnosed breast cancer is very low.
  • Physicians and patients can be assured that the risk of occult cancer is low in the setting of a normal contralateral MRI, an important fact when considering CPM after a diagnosis of unilateral breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lee J, Min W, Kim S, Son B: Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer.
  • : e11582 Background: Serum Her-2/neu has been known as molecular surrogating marker of predicting treatment response in Her-2 positive breast cancer.
  • METHODS: All breast cancers were tested by immunohistochemical stain and FISH for Her-2/neu before treatment.
  • Pathologic complete response (pCR) was considered as no residual tumor or remnant ductal carcinoma in situ, partial response (PR) was less than 50% decrease in maximal diameter in pathologic tumor size.
  • Serum Her-2/neu levels may serve to monitoring neoadjuvant therapy in Her-2/neu positive breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cortazar P, Johnson J, Justice R, Pazdur R: Adjuvant breast cancer: FDA approval overview. J Clin Oncol; 2009 May 20;27(15_suppl):e11529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant breast cancer: FDA approval overview.
  • : e11529 Background: Improved disease-free survival (DFS) in randomized controlled trials (RCT) is the primary basis for approval of adjuvant breast cancer (ABC) treatments.
  • RESULTS: DFS is a composite endpoint defined as the time from randomization to the earliest occurrence of invasive loco-regional recurrence, invasive contralateral breast cancer, DCIS, distant metastases, second primary tumors or death from any cause.
  • Trastuzumab approval as part of a treatment regimen was based on 4 clinical trials that showed improved DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964635.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Waintraub SE, Tuchman V: The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer.
  • : e11524 Background: Neoadjuvant Rx has been shown to downstage locally advanced breast cancer (LABC) to try to achieve a pathological complete response(PCR) and to convert mastectomy to lumpectomy.
  • Bevacizumab (B) was recently approved to treat metastatic breast cancer in combination with paclitaxel (P).
  • NSABP B-27 used preoperative doxorubicin(A) with cyclophosphamide (C) +- docetaxel (Doc) every 3 wks in primary operable breast cancer, yielding a 12.9% PCR with no residual invasive cancer from AC and 26.1% with the addition of Doc.
  • METHODS: Pts with Her2neu-negative locally advanced operable M0 breast cancer were treated initially with B 10mg/kg iv q 2w with Doc 100mg/m2 q 2w four times with pegfilgrastim given 24 hours after chemotherapy, followed by A 60mg/m2 and C 600mg/m2 q 2 weeks four 4 times with pegfilgrastim given 24 hours after chemotherapy with B 10mg/kg iv for the first AC course as the B was discontinued at least 6 weeks prior to definitive breast surgery.
  • RESULTS: 15 Her-2 neg women aged 35-61 were treated from 9/06-present for locally advanced primary operable breast cancer.
  • Of the first 12 post-operative evaluable pts that have completed all the pre- operative therapy, the results showed 5 PCR, including one pt with residual sub-cm DCIS, 7 pathological incomplete responses, yielding a 42% PCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964628.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Di Filippo F, Mottolese M, Botti C, Marandino F, Psaila A, Perri P, Di Filippo S, Pasqualoni R, Ferranti F, Buglioni S: A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation. J Clin Oncol; 2009 May 20;27(15_suppl):609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation.
  • : 609 Background: The aims of the study were 1) to assess the accuracy of a new intra-operative molecular diagnostic tool named OSNA, based on the measurement of cytokeratin 19 (CK19) mRNA, in the detection of axillary sentinel lymph node (SLN) metastases in patients with breast carcinoma 2) to determine the concordance of OSNA analysis with multilevel haematoxylin and eosin (H&E) and immunohistochemical (IHC) examination.
  • METHODS: A prospective series of 247 consecutive SLNs from 187 breast cancer patients was evaluated.
  • Two alternate slices were used for the intra-operative OSNA assay.
  • RESULTS: Pts characteristics: infiltrating ductal/infiltrating lobular/mucinous/medullar/DCIS: 130/10/1/1/25.
  • The method could be applied as a rapid and reliable intra-operative diagnostic tool thus preventing breast cancer patients from a diagnostic delay or second surgery due to a postoperatively diagnosed positive SLN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mates M, Hopman W, Madarnas Y: Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario. J Clin Oncol; 2009 May 20;27(15_suppl):e11614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario.
  • : e11614 Background: Preoperative chemotherapy (PCT) is the standard of care for locally advanced breast cancer (LABC).
  • As part of a multicentre provincial initiative we undertook a review of practice patterns and outcomes for women with LABC at our institution.
  • METHODS: We reviewed electronic and paper records for M<sub>0</sub> pts receiving PCT for LABC between 1995-2007 at our institution, collecting demographic, disease and treatment-related, and outcome variables.
  • Stage distribution: 10% IIB, 11% IIIA, 77% IIIB and 2% IIIC, of which 45% had inflammatory breast cancer (IBC).
  • At biopsy 90% were invasive ductal carcinoma, 36% were ER and PR(-) and 25% were her2(+).
  • Local therapy: mastectomy (M) in 82% of pts and partial M in 11%.
  • Axillary surgery was done in only 92% of pts (axillary node dissection 90%, sentinel node biopsy 1pt) and 7% had no definitive breast or axillary surgery due to local progression (3) or refusal (1).
  • At definitive surgery 10% of pts had no residual disease in breast or axilla and 3 pts had only DCIS present, for a pathologic (p)CR rate of 15% using MDACC criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Bandyopadhyay S, Nahleh Z, Ali Fehmi R, Arabi H, Sakr W, Munkarah A, Kruger M: Enhancer of zeste homologue 2 ( EZH-2) expression in breast cancer: a novel marker and potential target. J Clin Oncol; 2009 May 20;27(15_suppl):e22154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancer of zeste homologue 2 ( EZH-2) expression in breast cancer: a novel marker and potential target.
  • : e22154 Background: EZH-2 is a protein involved in cell cycle regulation; it belongs to the Polycomb group of proteins and has been suggested to be associated with aggressive breast cancer.
  • In hormone receptor negative (HR-) breast carcinomas, novel therapeutic targets are needed.
  • In our study we investigate the expression of EZH2 in a cohort of hormone receptor negative breast carcinomas.
  • METHODS: We identified a consecutive cohort of 84 cases of HR- breast carcinoma in 2005-2006, from the Pathology department archives.
  • Tumor grade, size, presence or absence of DCIS, lymph node status and Her2/neu expression were documented.
  • No correlation was seen with tumor grade, the presence or absence of DCIS and Her2/neu expression.
  • CONCLUSIONS: Our findings suggest that EZH2 is expressed in the majority of HR - breast cancer and is associated with aggressive breast carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Rahal A, Caron O, Bourgier C, Frebourg T, Bressac de Paillerets B, Barreau L, Pachet C, Mathieu M, Marsiglia H, Delaloge S: Influence of loco-regional radiation therapy on subsequent cancer risk among BC pts with p53 germline mutations. J Clin Oncol; 2009 May 20;27(15_suppl):11043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of loco-regional radiation therapy on subsequent cancer risk among BC pts with p53 germline mutations.
  • : 11043 Background: The management of breast cancer (BC) patients (pts) with germline p53 mutations, a rare genetic condition, is not the object of specific recommendations.
  • It remains discussed whether the knowledge of a germline p53 mutation may influence treatment (trt) choices and have prognostic importance.
  • PATIENTS AND METHODS: 9 pts have been diagnosed and treated in our institution within the past 11 years for BC as first tumor in the context of a documented germline p53 mutation.
  • RESULTS: Median age at diagnosis of primary BC was 32 (22-48).
  • Primary tumors were ductal carcinoma in situ (4), infiltrating ductal carcinoma (4), phyllode tumor (1).
  • Second primaries were sarcoma in 3/4 cases and 1 was papillary thyroid carcinoma.
  • CONCLUSIONS: Because of high risk of second breast primary and probably very high risk of radio-induced breast cancer, BC pts with germline p53 mutations should be advised bilateral prophylactic mastectomy and avoidance of radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of metabolic syndrome with triple-negative breast cancer.
  • : 1038 Background: Metabolic syndrome, a conglomerate of obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension is associated with an increased risk of breast cancer.
  • However, no clear association has been shown between the highly aggressive triple-negative breast cancer and metabolic syndrome.
  • METHODS: In a retrospective review we compared triple-negative and non-triple-negative breast cancer cases for the presence of metabolic syndrome by NCEP (National Cholesterol Education Program) or AACE (American Association of Clinical Endocrinologists) definitions.
  • Data on metabolic syndrome criteria, tumor size, grade, lymph node status, and ductal carcinoma in situ (DCIS) were reviewed.
  • RESULTS: The entire cohort of 176 patients (12.5% African-American) with median age 56.5 years (range 26-91 years) comprised of 86 triple-negative cases and 90 non-triple-negative cases.
  • A statistically significant association of triple-negative breast cancer with metabolic syndrome was observed.
  • According to the NCEP criteria 58.1% of triple negative patients had metabolic syndrome as compared to only 36.7% of non-triple negative patients (p = 0.004).
  • Consistently, by the AACE criteria 52.3% of triple negative patients had metabolic syndrome as compared to 34.4% of non-triple negative patients (p = 0.017).
  • Contrary to blood glucose, triglyceride, or HDL levels, which independently showed significant association with triple-negative breast cancer, hypertension, or BMI showed no independent association.
  • Additionally, triple-negative tumors displayed a significantly higher histologic grade and relative paucity of ductal carcinoma in situ (DCIS) when compared to the non-triple negative tumors (p < 0.001).
  • CONCLUSIONS: The data suggests that the metabolic syndrome is significantly more prevalent in triple-negative breast cancer patients when compared to the non-triple-negative patients.
  • Additionally, triple-negative breast cancer showed a significantly higher histologic grade and a relative absence of DCIS.
  • Whether the presence of metabolic syndrome preferentially increases the risk of developing triple-negative-breast cancer needs to be elucidated by future prospective studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Toussaint J, Durbecq V, Rouas G, Altintas S, Desmedt C, Larsimont D, Piccart M, Sotiriou C: CD10 expression and risk of relapse in DCIS. J Clin Oncol; 2009 May 20;27(15_suppl):e22053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression and risk of relapse in DCIS.
  • : e22053 Background: DCIS is a heterogeneous malignant condition of the breast with no standard of care.
  • The Van Nuys Prognostic Index (VNPI) is the most useful tool to predict local recurrence.
  • However, assessment of the VNPI score is not easy and many women with DCIS are offered the same treatment.
  • Experimental evidence has indicated that a local death of the myo-epithelial cells (MECs) in the DCIS is a pre-requisite to tumor invasion.
  • The aim of the present study was to retrospectively evaluate the prognostic value of CD10 in DCIS.
  • METHODS: CD10 expression was evaluated by qRT-PCR and immuno-histochemistry (IHC) using FFPE tissues on normal samples (N=11) and two independent DCIS populations: a training set (N=66) and a validating set (N=88).
  • RESULTS: MECs were the only cells that showed a CD10 staining using IHC in normal and DCIS samples.
  • In contrast, DCIS samples showed a wide range of CD10 expression levels.
  • Of interest, 66% of DCIS showed lower expression values of CD10 compared to normal tissues.
  • The group of DCIS with low expression of CD10 was statistically associated with higher risk of relapse [HR: 2.49 (CI.95%= 1.13-5.49), P= 0.02].
  • CONCLUSIONS: Decrease of CD10 expression in MECs is associated with higher risk of relapse in DCIS and it has the potential to improve DCIS management.
  • These promising results are currently being validated in a larger patient's series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Olson AL, Bevers T, Guzman M, Theriault RL, Hortobagyi GN, Hahn KM: Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol; 2009 May 20;27(15_suppl):e20506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center.
  • : e20506 Background: An essential component of cancer survivorship care includes the prevention and early detection of new cancers.
  • We sought to determine if documentation of appropriate cervical and/or colon cancer screening differed between BrCa survivors followed in our BC (patients < 5 yrs from diagnosis of invasive BrCa or with active BrCa issues) and those seen in our SvC (patients with history of DCIS or ≥ 5 yrs from invasive BrCa diagnosis).
  • 3) ≥ 12 months from BrCa diagnosis, 4) no active GYN or GI complaints.
  • RESULTS: BrCa survivors followed our SvC were significantly more likely to have provider documentation of both cervical and colon cancer screening than those followed in our BC (72% versus 22.7%, and 68.4% versus 14.5%, respectively; both p values <0.001).
  • Although nursing documentation of cervical cancer screening is required in both centers, SvC patients were more likely to have this documented than those in the BC (95.3% versus 56.5%, respectively; p <0.001).
  • Nursing documentation of colon cancer screening is required in SvC (84.2% documented) but not in the BC (3.5% documented).
  • CONCLUSIONS: BrCa survivors receiving care in our survivorship clinic were more likely to have nursing or provider documentation of cervical and/or colon cancer screening.
  • Strategies that trigger documentation of non-BrCa screening take advantage of the "teachable moment" during a routine visit- thereby promoting the long-term health of cancer survivors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960945.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Hamm C, Coroneos C: Case report of a 27-year-old male with DCIS. J Clin Oncol; 2009 May 20;27(15_suppl):e11635

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a 27-year-old male with DCIS.
  • : e11635 DCIS in a young male is rarely reported.
  • He presented with a strong family history of cancer on both maternal and paternal sides of his family including breast, lung (maternal) and melanoma, colon and pancreatic (paternal).
  • Upon histologic review of the sample, concurrent gyecomastia and ductal carcinoma in situ was discovered.
  • To date, only four cases of gynecomastia and DCIS have been described in younger male patients.
  • Since only 30 - 50% of patients with DCIS eventually develop invasive cancer in the subsequent 10 - 20 years, this figure in the general population may be higher.
  • This case underscores the importance of family history in any patient presenting with a breast mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961200.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hassett MJ, Weeks JC: Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. J Clin Oncol; 2009 May 20;27(15_suppl):6507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample.
  • : 6507 Background: We previously developed a simple, data-based strategy for selecting high-priority quality measures, and applied it to practice performance data from eight National Comprehensive Cancer Network (NCCN) centers to identify high-priority measures for breast cancer care.
  • We now seek to evaluate the generalizability of these results by identifying which measures rank highly when practice performance data from a nationally representative sample, rather than a select group of cancer centers, are used.
  • METHODS: Using SEER-Medicare data, we assessed practice performance for 9933 women 65-70 years old diagnosed 1998-2002 with non-metastatic invasive breast cancer.
  • The absence of oral hormone therapy and DCIS pathology data in SEER-Medicare precluded assessments of quality relative to the remaining measures.
  • The highest-ranking measures recommended chemotherapy for hormone-receptor positive tumors >1 cm, axillary node surgery and radiation after lumpectomy for stage I-II cancer, and no radiation after mastectomy for node-negative cancer <5 cm.
  • Excluding hormone therapy and DCIS measures, the 6 highest-ranking measures in the SEER-Medicare and NCCN analyses were identical.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964009.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Picarsic J, Brufsky A, Onisko A, Chivukula M: Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER+) and estrogen receptor negative (ER-) ductal carcinoma in situ (DCIS) patients with and without associated invasive carcinoma (IC). J Clin Oncol; 2009 May 20;27(15_suppl):e11523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER+) and estrogen receptor negative (ER-) ductal carcinoma in situ (DCIS) patients with and without associated invasive carcinoma (IC).
  • : e11523 Background: DCIS is a heterogeneous pre-invasive carcinoma with a spectrum of clinical behavior.
  • The specific aim of this study is to analyze the expression of these novel biological markers: FOXA1, GATA-3, with recognized markers: MIB-1(Ki-67) and HER2 /neu in DCIS patients with/without associated IC.
  • METHODS: Sixty-nine (69) cases of DCIS [(fifty two (52) cases in ER+; seventeen (17) in ER-] were retrieved from our Pathology database.
  • RESULTS: DCIS is categorized into low grade (LG) (nuclear grade 1 and 2), high grade (HG) (grade 3).
  • In the HGDCIS (n=48), four (4) cases had IC after a mean of 7.75 years; three cases of recurrent DCIS after a mean 6 years.
  • No recurrent IC or DCIS is seen in the LGDCIS (n=21) group.
  • (1) Decreased expression of GATA 3 is observed in HGDCIS ER- group may be a contributor to higher recurrence observed in this group (14%) versus (0%) in ER+ group. (2) A strong expression of FOXA, GATA3, low Ki-67 index, absent Her 2 expression are characteristically seen in our ER+ DCIS group, as previously described in IC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964618.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hawley S, Jagsi R, Hamilton AS, Graff J, Griggs JJ, Katz SJ: Factors associated with bilateral versus single mastectomy in a diverse, population-based sample of breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):6502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with bilateral versus single mastectomy in a diverse, population-based sample of breast cancer patients.
  • : 6502 Background: Rates of bilateral mastectomy are increasing in the U.S., even among women with cancer in only one breast.
  • The goal of this analysis was to assess correlates of bilateral mastectomy in a large, racially/ethnically diverse sample of breast cancer patients.
  • METHODS: All women with ductal carcinoma-in-situ and a 20% random sample of women with invasive breast cancer aged < 79 years who were diagnosed in 2002 and reported to the Detroit and Los Angeles SEER registries were surveyed shortly after receipt of surgical treatment (response rate, 77.4%; n = 1,844).
  • Independent variables included patient demographics, family history of breast cancer, tumor stage, and patient concerns about recurrence and body image.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. McKean HA, Reynolds C, Hoskin TL, Suman VJ, Grant CS, Erlander MG, Ma X, Ingle J, Goetz MP: Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence. J Clin Oncol; 2009 May 20;27(15_suppl):550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence.
  • : 550 Background: Ductal carcinoma in situ (DCIS) is a heterogeneous group of non-invasive cancers with varying propensity for recurrence.
  • There are no validated markers that identify patients at risk for invasive recurrence following lumpectomy.
  • HOXB13/IL17BR (H/I) is expressed in both DCIS and invasive cancer (Ma Cancer Cell.
  • 2004) and associated with recurrence in stage I cancer.
  • A 5-gene molecular grade index (MGI) distinguishes outcome in grade II disease (Ma Clin Cancer Res. 2008).
  • We sought to determine whether H/I or MGI was associated with invasive recurrence in resected DCIS.
  • METHODS: We identified patients at Mayo Rochester who underwent lumpectomy ± radiation for DCIS between 1988 and 2001 and performed a nested case/control study.
  • Cases were patients with ipsilateral invasive recurrence, matched to controls based on age, surgery date, length of follow-up, and adjuvant radiation.
  • DCIS was macrodissected from paraffin sections and RNA extracted to obtain H/I and MGI RT-PCR profiles.
  • RESULTS: 427 patients underwent lumpectomy for DCIS, and 33 were identified as possible cases.
  • Histologic review excluded 8 (non-sufficient tissue or DCIS recurrence without invasion).
  • CONCLUSIONS: These data suggest that both HOXB13/IL17BR and MGI can identify a subset of patients with surgically resected DCIS who are at risk for invasive recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Kwong A, Wong L, Wong C, Law F, Tang E, Chan W, Ma ES, Ford JM, West DW, Breast Cancer Genetics Study Group: Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22226

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
  • : e22226 Background: Breast cancers due to underlying germline BRCA1 and BRCA2 mutations are associated with particular pathological features that may differ from sporadic breast cancers.
  • We report clinical and pathologic characteristics of breast cancer in a clinical cohort of high risk Chinese women with BRCA mutations and those without mutations.
  • Breast cancer risk factors, other than family history, did not differ between carriers and non-carriers.
  • Mutation carriers were more likely to have a familial history of breast cancer (p=0.07) and personal and family history of ovarian cancer (p=0.005; p=0.007).
  • 23% of women diagnosed with DCIS had BRCA mutations compared with 11.4% of those with invasive cancers.
  • Overall 9.6% of non-BRCA cancers were TN whereas 25.9% of BRCA cancers were TN.
  • BRCA related breast cancer is associated with families with increasing number of first degree relatives with breast and/or ovarian cancers and were higher for DCIS cancers.
  • Prevalence of TN breast cancers was high compared to Caucasian cohorts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964090.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Santana-Davila R, Visscher DW, Vachon CM, Frost M, Vierkant RA, Anderson SS, Degnim AC, Hartmann LC: Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease. J Clin Oncol; 2009 May 20;27(15_suppl):1061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease.
  • : 1061 Background: Benign breast disease (BBD) is a significant risk factor for breast cancer (BC); however little is known about the aggressiveness of the BCs these patients develop.
  • Shared features between select atypias and low-grade DCIS have led some to speculate that a history of BBD portends the development of well-differentiated BCs.
  • METHODS: The Mayo BBD cohort includes 9,376 women who had benign breast biopsies from 1967-1991.
  • Tissue from the BCs was reviewed by a single breast pathologist (DWV).
  • RESULTS: Our cohort included 6,244 patients with nonproliferative disease (NP), 2,801 women with proliferative disease without atypia (PDWA), and 331 with atypical hyperplasias (AH).
  • With a median of 18 years of follow-up, 799 patients with BBD have developed breast cancer, 416 initially had NP, 313 had PDWA, and 70 AH.
  • The cancers were invasive ductal in 76.1% (n = 535), invasive lobular in 9.4% (n = 66), and DCIS alone in 14.5% (n = 102) patients.
  • In 537 cases the malignant tissue had a concurrent benign component consisting of NP in 24% (n = 129), PDWA in 25.1% (n = 135), and AH in 50.8% (n = 273).
  • In regards to tumor size, 69.6% had T1 tumors, 24.9% T2 tumors, and 5.5% T3 disease.
  • Breast cancer developed within 5 years from the initial BBD in 163 women (20%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Miura D, Saitoh Y, Iwatani T, Kawabata H, Inoshita N: Chromosome enumeration probe 17 (CEP) ratio to predict chemosensitivity in HER-2 overexpressing breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11600

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome enumeration probe 17 (CEP) ratio to predict chemosensitivity in HER-2 overexpressing breast cancer.
  • : e11600 Background: Precise assessment of HER-2 is critical in breast cancers and predicts benefit of trastuzumab (T).
  • To analyze the epidemiologic feature of C17 in Japanese patients, consecutive operable breast cancer patients during 05-07 treated in single institution were studied.
  • METHODS: HER-2 status of consecutive 307 patients excluding DCIS and whose specimens were poor quality for study, were analyzed with Pathvysion (FISH).
  • Pathological response following neoadjuvant chemotherapy (NACT) was assigned according to the Japanese Breast Cancer Society (G3; no invasive or in situ residual tumor in the breast, G2; up to two thirds of primary cancer cells having pathologically severe changes or disappearance, G1; up to one third to two thirds of primary cancer cells having pathologically severe changes or disappearance).
  • Six of 9 (67%) with C17 had G3 and 2 of 14 (14%) with non-C17 did G3.
  • CONCLUSIONS: C17 was found in 25% of Japanese operable breast cancer patients of which was similar to that of CALGB.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961037.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Jagsi R, Abrahamse P, Griggs JJ, Katz SJ: Adjuvant radiotherapy use in a population-based sample of breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy use in a population-based sample of breast cancer patients.
  • : 617 Background: Previous studies have suggested underutilization and socioeconomic disparities in use of adjuvant radiotherapy (RT) among patients with breast cancer.
  • METHODS: We evaluated data from 2260 survey respondents with nonmetastatic breast cancer, aged 20-79 years, diagnosed from June 2005-February 2007 in Detroit and Los Angeles and reported to SEER registries (72% response rate).
  • Patients were divided into 3 populations: DCIS pts undergoing breast conservation (BCS), invasive pts undergoing BCS, and invasive pts undergoing mastectomy.
  • These were then stratified based on recurrence risk in the absence of RT (3 groups based on tumor size and grade for DCIS pts, 2 groups separating pts over 70 with Stage I, ER+ tumors from others undergoing BCS for invasive disease, and 3 groups based on tumor size and nodal status for those undergoing mastectomy for invasive disease).
  • RESULTS: Among 306 pts undergoing BCS for DCIS, 85.6% received RT (77.9% of pts at low recurrence risk, 84.8% at intermediate risk, and 95.8% at high risk).
  • Among 1018 pts undergoing BCS for invasive disease, 93.6% received RT (83.6% of low-risk patients and 94.9% of others).
  • Among 661 pts undergoing mastectomy for invasive disease, 39.3% received RT (81.5% of pts at high-risk, 44.5% at intermediate-risk, and 12.1% at low risk).
  • Among pts receiving RT, delay was reported by 15.9% of the DCIS group, 19.5% of those treated for invasive disease after BCS, and 27.4% of those treated for invasive disease after mastectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961489.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Singer CF, Hudelist G, Fuchs E, Köstler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Lamm W, Lamm W, Rudas M, Kubista E: Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells.
  • : e22035 Background: HER-2 amplification and consecutive overexpression is a predictor for poor prognosis in breast cancer patients.
  • In addition, incomplete resection of HER2 overexpressing tumors leads to increased proliferation of residual breast cancer cells.
  • While the local release of cytokines is thought to be responsible for the malignant behaviour of remaining tumor tissue, the exact mechanism is still unknown.
  • METHODS: We have analyzed EGFR, activated (p)EGFR, and activated (p)HER2 protein expression in HER2 overexpressing and in non-HER2 overexpressing tumors from patients who underwent breast surgery and consecutive reexcision for involved margins, and compared expression levels by IHC.
  • RESULTS: While overall HER2 protein expression in the initial and the reexcised sample were comparable, we observed an increase in pHER2 in DCIS in both, HER2 overexpressing (16/21 vs 24/24; p=0.018, Chi Square test) and non-HER2 overexpressing tumors (3/28 vs 5/12; p=0.025, Chi Square test).
  • pHER2 was not increased in invasive tumors, regardless on whether the samples had been taken from a HER2 overexpressing (9/25 vs 6/17; p=0.261, Chi Square test), or a non-HER2 overexpressing tumor (1/27 vs 0/8; p=0.581, Chi Square test).
  • EGFR expression was only detected in 1/47 HER2 overexpressing primary tumors and 2/48 non-HER2 overexpressing tumors, and was undetectable in reexcised specimen.
  • CONCLUSIONS: Taken together, we have demonstrated an increase in HER2 receptor activation in incompletely resected preinvasive breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963151.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Rudloff U, Brogi E, McCormick B, Brockway JP, Goldberg JI, Wynveen CA, Reiner AS, Patil S, Van Zee KJ: The influence of margin width and volume of disease near margin on benefit of radiation therapy after breast-conserving surgery for DCIS: Results of long-term follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of margin width and volume of disease near margin on benefit of radiation therapy after breast-conserving surgery for DCIS: Results of long-term follow-up.
  • : 531 Background: There remains variation in the use of radiation (RT) in women with DCIS, despite prospective randomized trials documenting its benefit in reducing the risk of ipsilateral breast tumor recurrence (IBTR).
  • METHODS: Patients with DCIS treated with excision alone or excision plus radiation at our institution from 1991-1995 were identified.
  • A dedicated breast pathologist assessed margin width, number of involved ducts at closest margin, nuclear grade, and presence of necrosis and lobular neoplasia.
  • Following adjustment for other variables, higher volume of disease near the margin was associated with risk of IBTR in the no RT group (HR=3.37, p=0.002) and greater benefit of RT (HR 0.14; p=0.004).
  • Patients with higher volume of disease near the margin derive a greater benefit from the addition of RT.
  • Despite margins of ≥10mm, the risk of local recurrence remains substantial in patients with DCIS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Spiess BD: The potential role of perfluorocarbon emulsions in decompression illness. Diving Hyperb Med; 2010 Mar;40(1):28-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of perfluorocarbon emulsions in decompression illness.
  • Decompression illness (DCI) is an occasional occurrence in sport, professional, and military diving as well as a potential catastrophe in high-altitude flight, space exploration, mining, and caisson bridge construction.
  • DCI theoretically could be a success-limiting problem in escape from a disabled submarine (DISSUB).
  • Perfluorocarbon emulsions (PFCs) have previously been investigated as 'blood substitutes' with one approved by the United States Food and Drug Administration for the treatment of myocardial ischaemia.
  • This review examines approximately 30 years of research regarding the utilization of PFCs in gas embolism as well as experimental DCI.
  • To date, no humans have been treated with PFCs for DCI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23111836.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


54. Carrera E, Kurtz P, Badjatia N, Fernandez L, Claassen J, Lee K, Schmidt JM, Connolly ES, Marshall RS, Mayer SA: Cerebrovascular carbon dioxide reactivity and delayed cerebral ischemia after subarachnoid hemorrhage. Arch Neurol; 2010 Apr;67(4):434-9
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrovascular carbon dioxide reactivity and delayed cerebral ischemia after subarachnoid hemorrhage.
  • OBJECTIVE: To determine the predictors of impaired cerebrovascular reactivity (CVR) and the value of CVR in predicting delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH).
  • PATIENTS: Thirty-four consecutive patients with acute SAH who underwent measurement of changes in the middle cerebral artery mean blood flow velocity after carbon dioxide challenge.
  • MAIN OUTCOME MEASURE: Occurrence of DCI.
  • RESULTS: Delayed cerebral ischemia occurred in 10 patients (29%).
  • During period 1, there was only a trend toward lower CVR in patients who later developed DCI (1.1% vs 1.9% per 1-mm Hg increase in PCO(2); P = .07).
  • However, those who developed DCI had progressively lower CVR during periods 2 (0.7%/mm Hg vs 2.1%/mm Hg; P < .001) and 3 (0.6%/mm Hg vs 2.4%/mm Hg; P < .001).
  • Independent predictors of DCI included a decrease in CVR between periods 1 and 2 (P = .03) and a poor Hunt-Hess score (P = .04).
  • Impaired CVR at any point had a sensitivity for subsequent DCI of 91% and a specificity of 49%.
  • Progressive loss of normal CVR identifies patients at high risk for DCI, and persistently normal reactivity implies a low risk.
  • [MeSH-major] Brain Ischemia / etiology. Brain Ischemia / physiopathology. Cerebrovascular Circulation / physiology. Subarachnoid Hemorrhage / complications. Vasospasm, Intracranial / etiology. Vasospasm, Intracranial / physiopathology
  • [MeSH-minor] Adult. Aged. Carbon Dioxide / pharmacology. Cerebral Arteries / drug effects. Cerebral Arteries / metabolism. Cerebral Arteries / physiopathology. Female. Hemodynamics. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Risk Factors. Time Factors. Vasoconstriction / drug effects. Vasoconstriction / physiology


55. Ozyigit T, Egi SM, Denoble P, Balestra C, Aydin S, Vann R, Marroni A: Decompression illness medically reported by hyperbaric treatment facilities: cluster analysis of 1929 cases. Aviat Space Environ Med; 2010 Jan;81(1):3-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decompression illness medically reported by hyperbaric treatment facilities: cluster analysis of 1929 cases.
  • INTRODUCTION: The term decompression illness (DCI) describes maladies resulting from inadequate decompression, but there is little consensus concerning clinically useful DCI subclasses.
  • Our aim was to explore an objective DCI classification using multivariate statistics to assess naturally associated clusters of DCI manifestations.
  • We also evaluated their mapping onto other DCI classifications and investigated the association with therapeutic outcome.
  • The data were 1929 DCI cases reported by hyperbaric chambers to the Divers Alert Network (DAN America) from 1999-2003.
  • RESULTS: Four robust and highly significant clusters of DCI manifestations were demonstrated containing 300, 741, 333, and 555 patients.
  • The clusters mapped poorly onto traditional DCI categories (AGE, Type I DCS, Type II DCS), but more specifically onto the Perceived Severity Index (PSI).
  • All three classification methods (DCI, Cluster, PSI) predicted complete relief of manifestations equally well.
  • We conclude that cluster analysis is an objective method for classifying DCI manifestations independent of clinical judgment.
  • [MeSH-major] Decompression Sickness / classification. Decompression Sickness / epidemiology. Diving / adverse effects. Hyperbaric Oxygenation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Bayes Theorem. Cluster Analysis. Female. Humans. Male. Middle Aged. Multivariate Analysis. Reproducibility of Results. Retrospective Studies. Severity of Illness Index. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058731.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


56. van der Schaaf I, Wermer MJ, van der Graaf Y, Hoff RG, Rinkel GJ, Velthuis BK: CT after subarachnoid hemorrhage: relation of cerebral perfusion to delayed cerebral ischemia. Neurology; 2006 May 23;66(10):1533-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT after subarachnoid hemorrhage: relation of cerebral perfusion to delayed cerebral ischemia.
  • BACKGROUND: Delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) is difficult to predict.
  • The authors studied the relation between several parameters of brain perfusion at admission and development of DCI.
  • They assessed cerebral blood volume (CBV) and flow (CBF), mean transit time (MTT), and time to peak (TTP) for eight predefined regions of interest.
  • For patients with and without DCI, the authors compared perfusion quantitatively and semiquantitatively.
  • With receiver-operator characteristic (ROC) curves, the authors assessed the relationship between DCI and perfusion parameters.
  • RESULTS: DCI was not significantly related with quantitative perfusion values.
  • For the semiquantitative data, patients with DCI had significantly more asymmetry in perfusion, and ROC curves indicated a good relation (0.75 to 0.81).
  • Optimal threshold values distinguishing between patients with and without DCI were 0.77 for CBV and 0.72 for CBF ratios, and 0.87 seconds for MTT and 1.0 second for TTP differences.
  • CONCLUSIONS: Delayed cerebral ischemia (DCI) is related to perfusion asymmetry on admission CT perfusion (CTP).
  • The cerebral blood flow ratio (comparing contralateral regions of interest) seems the best prognosticator for development of DCI.
  • Further studies are needed to investigate the additional value of CTP to other prognosticators for DCI and to validate the chosen threshold values.
  • [MeSH-major] Brain / radiography. Brain Ischemia / radiography. Cerebral Angiography / methods. Cerebrovascular Circulation. Subarachnoid Hemorrhage / radiography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16717213.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Paddock SM, Edelen MO, Wenzel SL, Ebener P, Mandell W, Dahl J: Measuring changes in client-level treatment process in the therapeutic community (TC) with the Dimensions of Change Instrument (DCI). Am J Drug Alcohol Abuse; 2007;33(4):537-46
MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring changes in client-level treatment process in the therapeutic community (TC) with the Dimensions of Change Instrument (DCI).
  • The Dimensions of Change Instrument (DCI) measures treatment process in residential therapeutic community (TC) settings.
  • We present evidence of the reliability of the DCI for assessing both adult (N = 519) and adolescent (N = 474) client perceptions of treatment process.
  • The DCI factors significantly increase over time, with increases consistently seen across all DCI factors for adults.
  • We highlight areas for future DCI modifications to broaden its applicability to adolescents.
  • Our findings show that clinicians can use the DCI to evaluate adult client progress and target areas for improving quality of care.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668339.001).
  • [ISSN] 0095-2990
  • [Journal-full-title] The American journal of drug and alcohol abuse
  • [ISO-abbreviation] Am J Drug Alcohol Abuse
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01DA14969
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


58. Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ: Global and focal cerebral perfusion after aneurysmal subarachnoid hemorrhage in relation with delayed cerebral ischemia. Neuroradiology; 2008 Sep;50(9):813-20
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global and focal cerebral perfusion after aneurysmal subarachnoid hemorrhage in relation with delayed cerebral ischemia.
  • INTRODUCTION: The pathogenesis of delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) is unclear.
  • We assessed whether DCI relates to focal or global cerebral perfusion on admission and on follow-up imaging.
  • We compared global and focal (least perfused territory) perfusion in patients with DCI (n = 12), clinically stable patients (n = 7), and patients with non-DCI-related deterioration (n = 8).
  • RESULTS: Global cerebral blood flow (CBF) increased on follow-up: 29% (95% confidence interval (CI) 15% to 43%) in patients with DCI, 12% (95%CI -1% to 25%) in stable patients, and 20% (95%CI 4% to 36%) in patients with non-DCI-related deterioration.
  • Focal CBF decreased in patients with DCI, (-23%; 95%CI -58% to 12%) but increased in patients with non-DCI-related deterioration (23%; 95%CI -26% to 55%) and stable patients (7%; 95%CI -30% to 45%).On follow-up, global CBF was lower in patients with DCI (70.0 ml per 100 g/min) than in clinically stable patients (81.6; difference 11.6; 95%CI 0.8 to 22.5 ml per 100 g/min) but comparable to patients with non-DCI-related deterioration (67.6; difference -2.4; 95%CI -11.9 to 7.2 ml per 100 g/min).
  • Focal CBF was lower in patients with DCI (30.7) than in clinically stable patients (53.6; difference 22.9; 95%CI 5.1 to 40.6 ml per 100 g/min) and patients with non-DCI-related deterioration (46.6; difference 15.9; 95%CI -2.6 to 28.4 ml per 100 g/min) CONCLUSION: Our results suggest that DCI is more likely a focal than a global process.
  • [MeSH-major] Aneurysm, Ruptured / physiopathology. Brain Ischemia / etiology. Cerebrovascular Circulation / physiology. Intracranial Aneurysm / physiopathology. Subarachnoid Hemorrhage / complications. Subarachnoid Hemorrhage / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1985 Jan;62(1):59-67 [3917294.001]
  • [Cites] Crit Care Med. 2001 Jan;29(1):158-63 [11176177.001]
  • [Cites] Crit Care Resusc. 2005 Sep;7(3):206-12 [16545047.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):539-46 [3871846.001]
  • [Cites] Magn Reson Med. 2004 Apr;51(4):736-43 [15065246.001]
  • [Cites] Curr Opin Crit Care. 2006 Apr;12(2):103-11 [16543784.001]
  • [Cites] Neurosurgery. 1989 Mar;24(3):368-72 [2927610.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):446-53 [845630.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Apr;18(4):419-24 [9538907.001]
  • [Cites] Neurology. 2006 May 23;66(10 ):1533-8 [16717213.001]
  • [Cites] Neuroradiology. 2006 Sep;48(9):685-90 [16804690.001]
  • [Cites] Radiology. 1980 Dec;137(3):679-86 [7003648.001]
  • [Cites] J Neurosurg Sci. 1993 Mar;37(1):9-18 [8366371.001]
  • [Cites] Neurochirurgie. 2002 Dec;48(6):489-99 [12595805.001]
  • [Cites] Stroke. 2006 Feb;37(2):409-13 [16373646.001]
  • [Cites] Neurosurg Focus. 2006 Sep 15;21(3):E2 [17029341.001]
  • [Cites] Stroke. 2003 Apr;34(4):1084-104 [12677088.001]
  • [Cites] N Engl J Med. 2006 Jan 26;354(4):387-96 [16436770.001]
  • [Cites] Neurosurgery. 1988 Apr;22(4):654-61 [3287211.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):819-25; discussions 825-6 [11014420.001]
  • [Cites] Stroke. 2006 Apr;37(4):979-85 [16514093.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):985-6 [3131498.001]
  • [Cites] Stroke. 1982 Sep-Oct;13(5):601-11 [6812243.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):304-17; discussion 304-17 [15670379.001]
  • [Cites] Brain. 2001 Feb;124(Pt 2):249-78 [11157554.001]
  • [Cites] Stroke. 1999 Jan;30(1):93-9 [9880395.001]
  • [Cites] Neuroradiology. 2001 Jan;43(1):7-16 [11214653.001]
  • (PMID = 18548240.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


59. Lippmann J: Review of scuba diving fatalities and decompression illness in Australia. Diving Hyperb Med; 2008 Jun;38(2):71-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of scuba diving fatalities and decompression illness in Australia.
  • The aim of this study was to estimate the historical and current risk of death and decompression illness associated with scuba diving in Australia.
  • METHOD: Data were collected through comprehensive internet searches of various journals and electronic databases using appropriate general and medical search engines, hand searches of relevant journals, searches of the DAN Asia-Pacific dive fatality and decompression illness databases, and consultation with various recompression facilities, and diver certification agencies and dive industry bodies.
  • In addition, a total of 3,558 divers were treated for decompression illness in Australian chambers during 1995-2007 financial years.
  • Similarly, the incidence of decompression illness during that period in Australia was 10.74 per 100,000 dives or lower.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22692688.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


60. Vergouwen MD, van Geloven N, de Haan RJ, Kruyt ND, Vermeulen M, Roos YB: Increased cortisol levels are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care; 2010 Jun;12(3):342-5
Hazardous Substances Data Bank. SIMVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cortisol levels are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
  • In patients with aneurysmal subarachnoid hemorrhage (SAH), hyperglycemia, hypertension, and endothelium dysfunction are associated with the occurrence of delayed cerebral ischemia (DCI).
  • Therefore, the purpose of the present study was to investigate whether increased serum cortisol levels after aneurysmal SAH are associated with DCI occurrence.
  • DCI was defined as the gradual onset of new focal neurological impairment, and/or a decreased level of consciousness of at least 2 points as recorded on the Glasgow Coma Scale.
  • Eleven patients (35%) developed DCI.
  • Signs of DCI started at a median of 6 days (range 4-10 days).
  • Patients who developed DCI had significantly higher cortisol levels than patients without DCI (P = 0.006).
  • CONCLUSIONS: Increased serum cortisol levels after SAH are associated with DCI occurrence and might be the link between the associations of hyperglycemia and endothelium dysfunction with DCI.
  • It remains to be investigated whether the association between cortisol levels and DCI is independent from known prognostic baseline factors, such as amount of blood on admission CT scan.
  • [MeSH-major] Brain Ischemia / blood. Hydrocortisone / blood. Subarachnoid Hemorrhage, Traumatic / blood

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2000 Nov 14;102(20):2473-8 [11076819.001]
  • [Cites] Stroke. 1990 Aug;21(8):1156-61 [2389295.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):137-45 [7709776.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):645-9; discussion 649-50 [18824943.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):515-25 [632876.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):77-83 [16361599.001]
  • [Cites] JAMA. 1977 Sep 26;238(13):1374-6 [578192.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1382-5 [18403438.001]
  • [Cites] Br Heart J. 1974 Jul;36(7):697-706 [4415138.001]
  • [Cites] J Cereb Blood Flow Metab. 2009 Aug;29(8):1444-53 [19458605.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):658-67; discussion 667 [17415202.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1963 Dec;26:535-9 [14083227.001]
  • [Cites] J Cereb Blood Flow Metab. 2009 Oct;29(10 ):1734-41 [19584892.001]
  • [Cites] Brain. 1963 Jun;86:301-14 [14023946.001]
  • [Cites] J Neurol Sci. 1974 Jul;22(3):375-82 [4836663.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Nov;28(11):1761-70 [18628782.001]
  • (PMID = 20069390.001).
  • [ISSN] 1556-0961
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / von Willebrand Factor; AGG2FN16EV / Simvastatin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


61. Harding S, Gee P: Personality as a predisposing factor for DCI: a pilot study. Diving Hyperb Med; 2008 Sep;38(3):134-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personality as a predisposing factor for DCI: a pilot study.
  • This study aimed to identify differences in personality characteristics related to decompression illness (DCI) in recreational scuba divers.
  • A matched control group of nine divers (without DCI) and a research group of nine divers (with DCI) were recruited.
  • Following a chamber dive (control group), or treatment for DCI (study group), three psychometric scales - Locus of Control, Eysenck's Personality Questionnaire - Revised, and Sensation Seeking Scale - were administered together with a diving history questionnaire and questions on motoring.
  • One significant difference was identified and lay between engine sizes, with those experiencing DCI having cars with larger engines (P < 0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22692714.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


62. Klingmann C, Gonnermann A, Dreyhaupt J, Vent J, Praetorius M, Plinkert PK: Decompression illness reported in a survey of 429 recreational divers. Aviat Space Environ Med; 2008 Feb;79(2):123-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decompression illness reported in a survey of 429 recreational divers.
  • BACKGROUND: The purpose of this study was to investigate the influence of diving experience and diving techniques on the lifetime incidence of decompression illness (DCI).
  • There was an overall lifetime incidence of DCI of 1 per 5463 dives.
  • The complete study group showed an increased lifetime incidence of DCI with decreased diving experience (1.97-fold to 8.17-fold higher).
  • Of the divers, 27% reported severe DCI with neurological symptoms.
  • The lifetime incidence for severe DCI was 1 in 20,291 dives.
  • Again, lifetime incidence for severe DCI was increased with decreased diving certification level (1.1-fold to 13.7-fold higher).
  • Technical divers showed a DCI lifetime incidence of 1 to 8591 dives compared to the non-technical divers with a lifetime incidence of 1 to 5077 dives (not significant).
  • CONCLUSION: In our study population, the lifetime incidence of DCI was increased in divers with less diving experience.
  • If further studies confirm this finding, diving federations should be encouraged to intensify their efforts of educating divers and should limit diving time and depth in inexperienced divers.
  • [MeSH-major] Decompression Sickness / epidemiology. Diving / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aviat Space Environ Med. 2008 Aug;79(8):797-8 [18717122.001]
  • (PMID = 18309910.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Vergouwen MD, Bakhtiari K, van Geloven N, Vermeulen M, Roos YB, Meijers JC: Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab; 2009 Oct;29(10):1734-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
  • The pathogenesis of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) remains unknown.
  • As in patients with thrombotic thrombocytopenic purpura an A Disintegrin And Metalloprotease with ThromboSpondin repeats-13 (ADAMTS13) deficiency leads to higher concentrations of large von Willebrand factor (vWF) multimers resulting in microthrombosis, our purpose was to compare ADAMTS13 and vWF in patients with and without DCI after aneurysmal SAH.
  • Eleven patients (35%) developed DCI.
  • No differences were observed in baseline characteristics between patients with and without DCI.
  • Patients with DCI had a stronger decrease in ADAMTS13 activity, and a more profound increase in vWF antigen, vWF propeptide, and vWF activity in the first few days after the hemorrhage (P-values for difference in polynomial time trend 0.0001, 0.020, 0.004, and 0.188, respectively).
  • Our results suggest that microthrombosis has a role in the pathogenesis of DCI, as a result of decreased ADAMTS13 activity and endothelium dysfunction.
  • [MeSH-major] ADAM Proteins / metabolism. Brain Ischemia / enzymology. Subarachnoid Hemorrhage / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584892.001).
  • [ISSN] 1559-7016
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / von Willebrand Factor; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS13 protein, human
  •  go-up   go-down


64. Kasius KM, Frijns CJ, Algra A, Rinkel GJ: Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis; 2010;29(6):576-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.
  • BACKGROUND AND PURPOSE: A proinflammatory prothrombotic state may increase the risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH).
  • We studied the relationship of levels of leukocytes, platelets, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) with the development of DCI and with clinical outcome in patients with aneurysmal SAH.
  • METHODS: In 125 patients admitted within 72 h after aneurysmal SAH, we dichotomized initial blood levels at their median values and investigated the prediction of DCI with Cox proportional hazard analysis and of poor clinical outcome with logistic regression analysis.
  • We also analyzed concentrations before and after onset of DCI with the paired-samples t test and compared changes with those in patients without DCI.
  • RESULTS: During the development of DCI (unrelated to treatment), patients had a larger increase in counts of platelets (difference 49 x 10(9)/l; 95% CI: 2-98) and leukocytes (difference 2.6 x 10(9)/l; 95% CI: 0.4-5.0) than patients without DCI during the same period.
  • CRP increased during DCI and decreased in patients without DCI (difference 14 mg/l; 95% CI: -29 to 58).
  • None of the determinants at baseline predicted the development of DCI.
  • CONCLUSION: Counts of platelets and leukocytes disproportionally increase during the occurrence of DCI after aneurysmal SAH.
  • Drugs with anti-thrombotic or anti-inflammatory properties should be studied for prevention and treatment of DCI.
  • [MeSH-major] Brain Ischemia / blood. Leukocyte Count. Platelet Count. Subarachnoid Hemorrhage / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20375501.001).
  • [ISSN] 1421-9786
  • [Journal-full-title] Cerebrovascular diseases (Basel, Switzerland)
  • [ISO-abbreviation] Cerebrovasc. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


65. Tempel R, Severance HW: Proposing short-term observation units for the management of decompression illness. Undersea Hyperb Med; 2006 Mar-Apr;33(2):89-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposing short-term observation units for the management of decompression illness.
  • Decompression illness (DCI) is a potentially life-threatening disease, often requiring hyperbaric oxygen therapy (HBO2) for symptom resolution.
  • To evaluate this, we did a retrospective study of patients presenting with DCI at a major hyperbaric facility.
  • One hundred and two consecutive patients were evaluated with DCI diagnosis and receiving HBO2.
  • [MeSH-major] Decompression Sickness / therapy. High Pressure Neurological Syndrome / therapy. Hyperbaric Oxygenation. Monitoring, Physiologic / methods. Patient Discharge

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716058.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. MacDonald RD, O'Donnell C, Allan GM, Breeck K, Chow Y, DeMajo W, Peerbaye Y, Sawadsky B, Wax R: Interfacility transport of patients with decompression illness: literature review and consensus statement. Prehosp Emerg Care; 2006 Oct-Dec;10(4):482-7
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interfacility transport of patients with decompression illness: literature review and consensus statement.
  • OBJECTIVE: Decompression illness (DCI) is a potentially lethal complication of diving and may occur far from hyperbaric facilities.
  • The need for prompt transport to a hyperbaric facility often involves air medical transport, but this may exacerbate DCI.
  • The authors reviewed available literature to establish evidence-based transport strategies utilizing safe altitudes for patients, with DCI.
  • METHODS: MEDLINE, EMBASE, and materials from organizations with expertise in diving medicine were searched for the following terms: decompression sickness, caisson disease, hyperbaric oxygenation, depth intoxication, or diving.
  • Two reviewers independently selected relevant citations involving patients with DCI and air medical transport for review and consensus statement development by an expert working group.
  • Only two retrospective case series, including nine patients, specifically examined the effect of altitude on patients with DCI during transport.
  • CONCLUSIONS: The working group identified the paucity of clinical studies and evidence-based recommendations for air medical transport of patients with DCI.
  • [MeSH-major] Air Ambulances. Decompression Sickness / therapy. Hyperbaric Oxygenation / methods. Transportation of Patients

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997779.001).
  • [ISSN] 1090-3127
  • [Journal-full-title] Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors
  • [ISO-abbreviation] Prehosp Emerg Care
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


67. Newton HB, Burkart J, Pearl D, Padilla W: Neurological decompression illness and hematocrit: analysis of a consecutive series of 200 recreational scuba divers. Undersea Hyperb Med; 2008 Mar-Apr;35(2):99-106
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological decompression illness and hematocrit: analysis of a consecutive series of 200 recreational scuba divers.
  • Neurological complications are common in recreational divers diagnosed with decompression illness (DCI).
  • Prior reports suggest that hemoconcentration, with hematocrit values of 48 or greater, increase the risk for more severe and persistent neurological deficits in divers with DCI.
  • Herein we describe our experience with neurological DCI and hematocrit values in a large series of consecutively treated divers.
  • We performed a retrospective chart review of 200 consecutive recreational divers that received treatment for DCI.
  • In 177 of the 200 divers (88.5%), at least one manifestation of neurological DCI (mild, moderate, or severe) was present.
  • Neurological complications are common in recreational divers treated for DCI.
  • The hematocrit did not correlate with neurological DCI in male divers.
  • [MeSH-major] Decompression Sickness / blood. Diving / adverse effects. Hematocrit. High Pressure Neurological Syndrome / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500074.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Steeb J, Galhena AS, Nyadong L, Janata J, Fernández FM: Beta electron-assisted direct chemical ionization (BADCI) probe for ambient mass spectrometry. Chem Commun (Camb); 2009 Aug 21;(31):4699-701
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta electron-assisted direct chemical ionization (BADCI) probe for ambient mass spectrometry.
  • A new low activity (63)Ni ionization technique, beta electron-assisted direct chemical ionization (BADCI) is reported and applied to the analysis of active ingredients in solid pharmaceutical tablets without sample preparation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641814.001).
  • [ISSN] 1364-548X
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Sivertsen W, Risberg J, Norgård G: [Patent foramen ovale and decompression illness in divers]. Tidsskr Nor Laegeforen; 2010 Apr 22;130(8):834-8
Genetic Alliance. consumer health - Patent Foramen Ovale.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Patent foramen ovale and decompression illness in divers].
  • BACKGROUND: About 25 % of the population has patent foramen ovale, and the condition has been assumed to be a causal factor in decompressive illness.
  • The present study explored a possible relationship between a patent foramen ovale and the risk for decompression illness in divers, if there are categories of divers that should be screened for the condition and what advice should be given to divers with this condition.
  • RESULTS: The risk of decompression illness for divers with a persistent foramen ovale is about five times higher than that in divers without this condition, but the absolute risk for decompression illness is only 2.5 after 10,000 dives.
  • A causal association has not been shown between patent foramen ovale and decompression illness.
  • INTERPRETATION: We do not recommend screening for patent foramen ovale in divers because the absolute risk of decompression illness is small and transcatheter closure is only indicated after decompression illness in some occupational divers.
  • [MeSH-major] Decompression Sickness / etiology. Diving / injuries. Foramen Ovale, Patent / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418929.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 41
  •  go-up   go-down


70. Yousef K, Crago E, Kuo CW, Horowitz M, Hravnak M: Predictors of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a cardiac focus. Neurocrit Care; 2010 Dec;13(3):366-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a cardiac focus.
  • Delayed cerebral ischemia (DCI) is also a complication of aSAH.
  • We sought to determine whether (1) DCI could be predicted by demographics, aSAH severity/aneurysm location, or aSAH-associated myocardial injury (SAHMI), and (2) DCI is associated with increased mortality after aSAH.
  • METHODS: Prospective longitudinal study of 149 aSAH subjects with definitive DCI evaluation, age 18-75 years, Hunt and Hess (HH) ≥ 3, and/or Fisher ≥ 2, and admitted to the Neurovascular ICU.
  • DCI was defined by the presence of neurological deterioration accompanied by evidence of abnormal cerebral blood flow.
  • RESULTS: Subjects were 48% DCI(+) and 52% DCI(-).
  • DCI(+) subjects had more severe aSAH [HH (P = 0.002), Fisher (P = 0.004), admission Glasgow Coma Scale (P = 0.018)].
  • More DCI(+) subjects had pulmonary congestion than DCI(-) subjects (63 vs. 39%, P = 0.003).
  • On echocardiogram, cardiac output (CO, liters per minute [LPM]) was significantly higher in DCI(+) than in DCI(-) subjects (6 ± 2 vs. 5 ± 1 LPM; P = 0.015).
  • Multivariate analysis identified CO and Fisher grade as independent predictors of DCI (P = 0.02, 0.019).
  • For each 1 LPM increase in CO, the odds of DCI increased by 1.5 (95% CI: 1.1-2.1).
  • Fisher grade 4 increased the odds of DCI by 6.5 compared to Fisher grade 2 (95% CI: 1.6-25.8).
  • After controlling for Fisher grade, CO remained an independent predictor of DCI (P = 0.02).
  • Three-month mortality rate was not significantly different between DCI groups, P = 0.786.
  • CONCLUSION: Elevated CO and Fisher grade are predictors of DCI after aSAH.
  • However, prevention of DCI may not decrease mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 2001 Sep;32(9):2012-20 [11546890.001]
  • [Cites] Neurocrit Care. 2010 Jun;12(3):342-5 [20069390.001]
  • [Cites] Neuroradiology. 2009 Dec;51(12):813-9 [19623472.001]
  • [Cites] Stroke. 2009 Nov;40(11):3478-84 [19713541.001]
  • [Cites] Neurosurgery. 2009 Aug;65(2):316-23; discussion 323-4 [19625911.001]
  • [Cites] Cerebrovasc Dis. 2009;27(6):579-84 [19390184.001]
  • [Cites] Stroke. 2009 Jun;40(6):1963-8 [19359629.001]
  • [Cites] Neurocrit Care. 2009;10(3):287-94 [19184553.001]
  • [Cites] Neurology. 2009 Feb 17;72(7):635-42 [19221297.001]
  • [Cites] Neuroradiology. 2008 Sep;50(9):813-20 [18548240.001]
  • [Cites] Cerebrovasc Dis. 2008;26(1):71-8 [18525201.001]
  • [Cites] Neurocrit Care. 2008;8(3):398-403 [18087680.001]
  • [Cites] Acta Neurochir (Wien). 2006 Aug;148(8):853-8; discussion 858 [16791433.001]
  • [Cites] Neurology. 2006 May 23;66(10):1533-8 [16717213.001]
  • [Cites] Circulation. 2005 Nov 1;112(18):2851-6 [16267258.001]
  • [Cites] Neuroimaging Clin N Am. 1997 Nov;7(4):659-68 [9336491.001]
  • [Cites] Stroke. 1997 Mar;28(3):660-4 [9056628.001]
  • [Cites] Neurosurg Rev. 1993;16(1):15-25 [8483515.001]
  • [Cites] Stroke. 1992 Oct;23(10):1416-9 [1412577.001]
  • [Cites] Stroke. 1988 Oct;19(10):1250-6 [3176085.001]
  • [Cites] Stroke. 1985 Jul-Aug;16(4):591-4 [4024173.001]
  • [Cites] Acta Neurol Scand. 2004 Oct;110(4):248-53 [15355489.001]
  • [Cites] Neurosurgery. 2003 May;52(5):1025-31; discussion 1031-2 [12699543.001]
  • [Cites] Stroke. 2000 May;31(5):1054-61 [10797165.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):905-14 [11337336.001]
  • [Cites] Stroke. 1999 Nov;30(11):2268-71 [10548655.001]
  • (PMID = 20645025.001).
  • [ISSN] 1556-0961
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NINR NIH HHS / NR / R01 NR004339; United States / NINR NIH HHS / NR / NR004339-12; United States / NINR NIH HHS / NR / R01 NR004339-12; United States / NHLBI NIH HHS / HL / R01 HL074316
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS301046; NLM/ PMC3131087
  •  go-up   go-down


71. Low D, Healy D, Rasburn N: The use of the BERCI DCI Video Laryngoscope for teaching novices direct laryngoscopy and tracheal intubation. Anaesthesia; 2008 Feb;63(2):195-201
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of the BERCI DCI Video Laryngoscope for teaching novices direct laryngoscopy and tracheal intubation.
  • The Karl Storz BERCI DCI Video Laryngoscope provides a video image for the trainer and a direct view identical to that of a standard laryngoscope for the trainee.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211452.001).
  • [ISSN] 1365-2044
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


72. Dankbaar JW, de Rooij NK, Velthuis BK, Frijns CJ, Rinkel GJ, van der Schaaf IC: Diagnosing delayed cerebral ischemia with different CT modalities in patients with subarachnoid hemorrhage with clinical deterioration. Stroke; 2009 Nov;40(11):3493-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing delayed cerebral ischemia with different CT modalities in patients with subarachnoid hemorrhage with clinical deterioration.
  • BACKGROUND AND PURPOSE: Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage worsens the prognosis and is difficult to diagnose.
  • We investigated the diagnostic value of noncontrast CT (NCT), CT perfusion (CTP), and CT angiography (CTA) for DCI after clinical deterioration in patients with subarachnoid hemorrhage.
  • METHODS: We prospectively enrolled 42 patients with subarachnoid hemorrhage with clinical deterioration suspect for DCI (new focal deficit or Glasgow Coma Scale decrease >or=2 points) within 21 days after hemorrhage.
  • The gold standard was the clinical diagnosis DCI made retrospectively by 2 neurologists who interpreted all clinical data, except CTP and CTA, to rule out other causes for the deterioration.
  • Radiologists interpreted NCT and CTP images for signs of ischemia (NCT) or hypoperfusion (CTP) not localized in the neurosurgical trajectory or around intracerebral hematomas, and CTA images for presence of vasospasm.
  • Diagnostic values for DCI of NCT, CTP, and CTA were assessed by calculating sensitivities, specificities, positive predictive values, and negative predictive values with 95% CIs.
  • Of the remaining 39 patients, 25 had DCI and 14 did not.
  • CONCLUSIONS: As a diagnostic tool for DCI, qualitative assessment of CTP is overall superior to NCT and CTA and could be useful for fast decision-making and guiding treatment.
  • [MeSH-major] Brain Ischemia / pathology. Brain Ischemia / radiography. Subarachnoid Hemorrhage / pathology. Subarachnoid Hemorrhage / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762703.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Nikolaev VP: [Theoretical evaluation of the risk of decompression illness during simulated extravehicular activity]. Aviakosm Ekolog Med; 2008 May-Jun;42(3):27-33
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Theoretical evaluation of the risk of decompression illness during simulated extravehicular activity].
  • Theoretical analysis of the risk of decompression illness (DI) during extravehicular activity following the Russian and NASA decompression protocols (D-R and D-US, respectively) was performed.
  • In contrast to the tradition approach to decompression stress evaluation by the factor of tissue supersaturation with nitrogen, our probabilistic theory of decompression safety provides a completely reasoned evaluation and comparison of the levels of hazard of these decompression protocols.
  • [MeSH-major] Decompression Sickness / etiology. Extravehicular Activity / adverse effects. Models, Theoretical. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Risk Assessment / methods. Space Flight

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055008.001).
  • [ISSN] 0233-528X
  • [Journal-full-title] Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine
  • [ISO-abbreviation] Aviakosm Ekolog Med
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Gases
  •  go-up   go-down


74. Kruyt ND, Roos YW, Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ, Biessels GJ: High mean fasting glucose levels independently predict poor outcome and delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry; 2008 Dec;79(12):1382-5
MedlinePlus Health Information. consumer health - Blood Sugar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High mean fasting glucose levels independently predict poor outcome and delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage.
  • BACKGROUND: Hyperglycaemia has been related to poor outcome and delayed cerebral ischaemia (DCI) after aneurysmal subarachnoid haemorrhage (aSAH).
  • OBJECTIVE: This study aimed to assess whether in patients with aSAH, levels of mean fasting glucose within the first week predict poor outcome and DCI better than single admission glucose levels alone.
  • METHODS: Data on non-diabetic patients admitted within 48 h after aSAH with at least two fasting glucose assessments in the first week were retrieved from a prospective database (n = 265).
  • The association of admission glucose or mean fasting glucose, dichotomised at the median levels, with outcome was assessed using logistic regression, and for DCI using Cox regression.
  • To explore whether the association between glucose levels and outcome was mediated by DCI, we adjusted for DCI.
  • The crude and adjusted hazard ratios for DCI were 1.7 (1.1 to 2.5) and 1.4 (0.9 to 2.1) for high admission glucose and 2.0 (1.3 to 3.0) and 1.7 (1.1 to 2.7) for high mean fasting glucose.
  • After adjusting for DCI, the odds ratios on poor outcome for high mean fasting glucose decreased only marginally.
  • CONCLUSIONS: Compared with high admission glucose, high mean fasting glucose, representing impaired glucose metabolism, is a better and independent predictor of poor outcome and DCI.
  • DCI is not the key determinant in the relationship between high fasting glucose and poor outcome.
  • [MeSH-major] Blood Glucose / analysis. Brain Ischemia / blood. Brain Ischemia / diagnosis. Subarachnoid Hemorrhage / blood. Subarachnoid Hemorrhage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403438.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


75. Sayer MDj, Ross JA, Wilson CM: Analyses of treatment for divers with actual or suspected decompression illness. Diving Hyperb Med; 2009 Sep;39(3):126-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of treatment for divers with actual or suspected decompression illness.
  • INTRODUCTION: We examined national and single-centre datasets in Scotland to determine any trends in the treatment of diving-related disease and to assess how the choice of first treatment may be linked to the divers' condition on referral and on discharge.
  • (1) 300 divers treated for actual or suspected decompression illness by the Dunstaffnage Hyperbaric Unit (Oban) between 1972 and 2007; and (2) 536 divers treated by the Scottish recompression chamber network between 1991 and 2003 (some data were common to both sets).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22753242.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


76. Sayer MDj, Akroyd J, Williams GD: Comparative incidences of decompression illness in repetitive, staged, mixed-gas decompression diving: is 'dive fitness' an influencing factor? Diving Hyperb Med; 2008 Jun;38(2):62-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative incidences of decompression illness in repetitive, staged, mixed-gas decompression diving: is 'dive fitness' an influencing factor?
  • Wreck diving at Bikini Atoll consists of a relatively standard series of decompression dives with maximum depths in the region of 45-55 metres' sea water (msw).
  • In a typical week of diving at Bikini, divers can perform up to 12 decompression dives to these depths over seven days; on five of those days, divers can perform two decompression dives per day.
  • All the dives employ multi-level, staged decompression schedules using air and surface-supplied nitrox containing 80% oxygen.
  • Bikini is serviced by a single diving operator and so a relatively precise record exists both of the actual number of dives undertaken and of the decompression illness incidents both for customer divers and the dive guides.
  • The dive guides follow exactly the dive profiles and decompression schedules of the customers.
  • Each dive guide will perform nearly 400 decompression dives a year, with maximum depths mostly around 50 msw, compared with an average of 10 (maximum of 12) undertaken typically by each customer diver in a week.
  • The incidence of decompression illness for the customer population (presumed in the absence of medical records) is over ten times higher than that for the dive guides.
  • The physiological reasons for such a marked difference are discussed in terms of customer demographics and dive-guide acclimatization to repetitive decompression stress.
  • The rates of decompression illness for a range of diving populations are reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22692686.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


77. MacKenzie TA, Titus-Ernstoff L, Vacek PM, Geller B, Weiss JE, Goodrich ME, Carney PA: Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control; 2007 Nov;18(9):939-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography.
  • OBJECTIVE: To examine the association between breast density and risk of breast ductal carcinoma in situ (DCIS).
  • METHODS: We assessed breast density in relation to DCIS risk using combined data from statewide mammography registries in NH and VT.
  • The prospective analyses were based on 572 DCIS cases arising in 154,936 women (58,496 premenopausal and 96,440 postmenopausal).
  • Breast density was scored by community radiologists using BIRADS categories (fatty, scattered density, heterogeneous density, extreme density).
  • RESULTS: In premenopausal women, based on 157 cases, the RR for DCIS risk were 0.29 (95% CI: 0.0.04, 2.24) for fatty breasts, 2.06 (95% CI: 1.39, 3.05) for heterogeneous density, and 2.40 (95% CI: 1.47, 3.91) for extreme density, relative to scattered density.
  • In postmenopausal women, based on 369 cases, the RR for DCIS risk were 0.58 (95% CI: 0.37, 0.93) for fatty breasts, 1.41 (95% CI: 1.12, 1.78) for heterogeneous density, and 1.49 (95% CI: 0.93, 2.37) for extreme density, relative to scattered density.
  • The possible interaction between breast density and menopausal status in relation to DCIS risk was not statistically significant.
  • CONCLUSIONS: We observed an association between breast density and DCIS risk.
  • Although the association seemed stronger in premenopausal women, there was no evidence of an interaction involving breast density and menopausal status.

  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638106.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA086082; United States / NCI NIH HHS / CA / U01 CA70013; United States / NCI NIH HHS / CA / U01 CA86082
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Poff DJ, Wong R, Bulsara M: Acute decompression illness and serum s100beta levels: a prospective observational pilot study. Undersea Hyperb Med; 2007 Sep-Oct;34(5):359-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute decompression illness and serum s100beta levels: a prospective observational pilot study.
  • As there are no published data on serum S100beta determinations in recreational divers affected by decompression illness (DCI) this pilot study determines whether S100beta is a possible biochemical marker of DCI worthy of further investigation.
  • METHODS: Venous blood samples were drawn from patients diagnosed with, and treated for acute DCI at a hyperbaric facility and analysed for serum S100beta concentration and Creatine Kinase (CK) activity.
  • CONCLUSION: S100beta is not a clinically useful serum marker of acute DCI.
  • [MeSH-major] Decompression Sickness / blood. S100 Proteins / blood
  • [MeSH-minor] Acute Disease. Adult. Biomarkers / blood. Creatine Kinase / blood. Female. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019087.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / S100 Proteins; EC 2.7.3.2 / Creatine Kinase
  •  go-up   go-down


79. Stein SC, Browne KD, Chen XH, Smith DH, Graham DI: Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery; 2006 Oct;59(4):781-7; discussion 787-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study.
  • OBJECTIVE: Recent findings have cast doubt on vasospasm as the sole cause of delayed cerebral ischemia after subarachnoid hemorrhage.
  • The density (burden) of the latter was calculated blindly and correlated with evidence for ischemia and with the amount of subarachnoid blood.
  • RESULTS: There is a strong correlation between microclot burden and delayed cerebral ischemia.
  • Patients with clinical or radiological evidence of delayed ischemia had mean microclot burdens of 10.0/cm2 (standard deviation [SD], +/-6.6); those without had mean burdens of 2.8 (SD, +/-2.6), a highly significant difference (P = 0.002).
  • There is also significant association (P = 0.001) between microclot burden and histological evidence of ischemia, with the mean burdens being 10.9 in sections exhibiting severe ischemia and 4.1 in those in which ischemia was absent.
  • In delayed ischemia, the numbers rise again late in the first week and remain high until after the second week.
  • In contrast, the average clot burden is low in patients dying without developing delayed ischemia.
  • CONCLUSION: Thromboembolism after subarachnoid hemorrhage may contribute to delayed cerebral ischemia, which parallels that caused by vasospasm.
  • [MeSH-major] Brain Ischemia / etiology. Subarachnoid Hemorrhage / complications. Thromboembolism / etiology
  • [MeSH-minor] Adult. Brain / pathology. Cadaver. Female. Humans. Male. Medical Records. Middle Aged. Pilot Projects. Severity of Illness Index. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915120.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. van der Schaaf I, Wermer MJ, van der Graaf Y, Velthuis BK, van de Kraats CI, Rinkel GJ: Prognostic value of cerebral perfusion-computed tomography in the acute stage after subarachnoid hemorrhage for the development of delayed cerebral ischemia. Stroke; 2006 Feb;37(2):409-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of cerebral perfusion-computed tomography in the acute stage after subarachnoid hemorrhage for the development of delayed cerebral ischemia.
  • BACKGROUND AND PURPOSE: Delayed cerebral ischemia (DCI) is an important cause of death and disability after subarachnoid hemorrhage.
  • We studied the additional prognostic value of brain perfusion to 3 established predictors (age, clinical condition on admission, and amount of subarachnoid blood) for the development of DCI.
  • For each patient, we determined cerebral blood flow (CBF) ratios of prespecified opposite regions of interest and the 3 established predictors.
  • RESULTS: The CBF ratio was an independent predictor for the development of DCI (HR, 0.63; 95% CI, 0.46 to 0.86) as was clinical condition (HR, 1.47; 95% CI, 1.01 to 2.13).
  • CONCLUSIONS: The CBF ratio is an independent predictor for the development of DCI and can contribute to a better identification of patients at high risk for DCI.
  • [MeSH-major] Brain Ischemia / pathology. Subarachnoid Hemorrhage / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373646.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Klingmann C, Praetorius M, Baumann I, Plinkert PK: Barotrauma and decompression illness of the inner ear: 46 cases during treatment and follow-up. Otol Neurotol; 2007 Jun;28(4):447-54
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barotrauma and decompression illness of the inner ear: 46 cases during treatment and follow-up.
  • MATERIALS AND METHODS: The medical records were used to study the cases of 18 divers treated for inner ear decompression illness on 20 occasions and 26 divers who had inner ear barotrauma.
  • The symptoms of the disorder at the beginning of treatment, latency period before the first therapeutic measures, kind of initial therapy, symptoms after the accident, and hearing and balance functions at the last examination in our clinic were assessed.
  • Divers with inner ear decompression illness were examined via means of transcranial or carotid Doppler ultrasonography for the presence of a vascular right-to-left (R/L) shunt.
  • RESULTS: Of 18 divers with inner ear decompression illness, 17 reported vertigo as the main symptom.
  • In one diver, the inner ear decompression illness was manifested bilaterally.
  • The divers with inner ear decompression illness had been treated with hyperbaric oxygen therapy in 14 of 20 cases; the average latency period before the start of therapy was 40 hours (median, 10 h).
  • CONCLUSION: We describe for the first time a patient with bilateral manifestation of inner ear decompression illness.
  • Inner ear decompression illness is frequently associated with a R/L shunt; therefore, after a diving accident, the patient's fitness to dive should be assessed via a specialist in diving medicine.
  • Both decompression illness and barotrauma of the inner ear result in residual cochleovestibular damage in more than three of four patients.
  • [MeSH-major] Barotrauma / complications. Decompression Sickness / complications. Ear, Inner / injuries
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Audiometry. Female. Follow-Up Studies. Functional Laterality. Hearing Loss / etiology. Humans. Hyperbaric Oxygenation. Male. Middle Aged. Prednisolone / therapeutic use. Pulmonary Heart Disease / complications. Pulmonary Heart Disease / ultrasonography. Retrospective Studies. Vertigo / etiology

  • MedlinePlus Health Information. consumer health - Barotrauma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17417111.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


82. Bennett M, Mitchell SJ, Lehm JP, Wasiak J: Recompression and adjunctive therapy for decompression illness: a systematic review of randomised controlled trials. Diving Hyperb Med; 2008 Jun;38(2):91-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recompression and adjunctive therapy for decompression illness: a systematic review of randomised controlled trials.
  • INTRODUCTION: Decompression illness (DCI) results from bubble formation in the blood or tissues following the breathing of compressed gas.
  • Recompression is the universally accepted standard for the treatment of DCI, but a number of strategies have been suggested in order to improve the outcome.
  • METHODS: We performed a systematic search of the literature in December 2007 for randomised controlled trials of DCI therapy, and made an analysis of pre-determined clinical outcomes.
  • There was a reduction in the number of compressions required with the addition of the non-steroidal anti-inflammatory drug (NSAID) tenoxicam to routine recompression therapy (P = 0.01) but no evidence of improved effectiveness (relative risk (RR) of residual symptoms 1.04, P = 0.58).
  • CONCLUSIONS: There is no randomised evidence concerning the effectiveness of recompression for DCI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22692691.001).
  • [ISSN] 1833-3516
  • [Journal-full-title] Diving and hyperbaric medicine
  • [ISO-abbreviation] Diving Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


83. Ducruet AF, Gigante PR, Hickman ZL, Zacharia BE, Arias EJ, Grobelny BT, Gorski JW, Mayer SA, Connolly ES Jr: Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab; 2010 Apr;30(4):676-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage.
  • Despite extensive effort to elucidate the cellular and molecular bases for delayed cerebral injury after aneurysmal subarachnoid hemorrhage (aSAH), the pathophysiology of these events remains poorly understood.
  • Recently, much work has focused on evaluating the genetic underpinnings of various diseases in an effort to delineate the contribution of specific molecular pathways as well as to uncover novel mechanisms.
  • Far less work has centered on the genetic determinants of cerebral vasospasm, the predisposition to delayed cerebral injury, and the determinants of ensuing functional outcome after aSAH.
  • To this end, we present a systematic review of 21 studies suggesting a genetic basis for clinical outcome after aSAH, with a special emphasis on the pathogenesis of cerebral vasospasm and delayed cerebral ischemia.
  • [MeSH-major] Brain Ischemia / physiopathology. Subarachnoid Hemorrhage. Vasospasm, Intracranial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2003 Jul;53(1):123-33; discussion 133-5 [12823881.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):391-6; discussion 396-7 [14572957.001]
  • [Cites] Br J Neurosurg. 1995;9(3):403-12 [7546361.001]
  • [Cites] Nat Med. 1996 Jan;2(1):41-5 [8564837.001]
  • [Cites] Cardiovasc Res. 1995 Oct;30(4):493-500 [8574997.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):141-5; discussion 145-6 [8805150.001]
  • [Cites] Physiol Rev. 1996 Oct;76(4):967-1003 [8874491.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):562-7; discussion 567-8 [8875487.001]
  • [Cites] Neurosurgery. 1997 Aug;41(2):344-9; discussion 349-50 [9257301.001]
  • [Cites] Neurochem Res. 1997 Oct;22(10):1249-55 [9342729.001]
  • [Cites] Neurology. 1998 Apr;50(4):876-83 [9566366.001]
  • [Cites] J Neurotrauma. 1998 Aug;15(8):573-85 [9726257.001]
  • [Cites] Stroke. 1998 Sep;29(9):1882-7 [9731613.001]
  • [Cites] Stroke. 1998 Sep;29(9):1930-5; discussion 1935-6 [9731621.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Sep;18(9):978-90 [9740101.001]
  • [Cites] Stroke. 1999 Feb;30(2):450-5; discussion 455-6 [9933286.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1069-71 [10213549.001]
  • [Cites] Acta Neurochir Suppl. 1999;73:89-92 [10494348.001]
  • [Cites] Circulation. 1999 Oct 5;100(14):1515-20 [10510054.001]
  • [Cites] Neurology. 1999 Oct 12;53(6):1308-11 [10522889.001]
  • [Cites] Pharmacol Ther. 2005 Jan;105(1):23-56 [15626454.001]
  • [Cites] Neurosurg Focus. 2004 Nov 15;17(5):E7 [15633984.001]
  • [Cites] Trends Cardiovasc Med. 2005 Jan;15(1):24-34 [15795160.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):1238-44 [15824354.001]
  • [Cites] J Neurol. 2005 Apr;252(4):417-22 [15726267.001]
  • [Cites] Stroke. 2005 Sep;36(9):2027-31 [16051898.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):558-64; discussion 558-64 [16145536.001]
  • [Cites] Neurosurg Focus. 2002 Mar 15;12(3):ECP1 [16212317.001]
  • [Cites] Proteomics. 2006 Jan;6(2):427-37 [16342244.001]
  • [Cites] Genetics. 2006 Jan;172(1):687-91 [16204206.001]
  • [Cites] Acta Neurol Scand. 2006 Nov;114(5):315-9 [17022778.001]
  • [Cites] Neurosurg Focus. 2006;21(3):E2 [17029341.001]
  • [Cites] Neurosurg Focus. 2006;21(3):E3 [17029342.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4):781-7; discussion 787-8 [16915120.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4):775-9; discussion 779-80 [17038943.001]
  • [Cites] J Korean Med Sci. 2006 Oct;21(5):922-6 [17043430.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1329-35 [16926234.001]
  • [Cites] Brain. 2006 Dec;129(Pt 12):3224-37 [17067993.001]
  • [Cites] Neurosurgery. 2007 Feb;60(2):213-25; discussion 225-6 [17290171.001]
  • [Cites] J Neurosurg. 2007 Feb;106(2):245-9 [17410707.001]
  • [Cites] Cerebrovasc Dis. 2004;17(1):53-60 [14530638.001]
  • [Cites] Acta Neurol Scand. 2004 Mar;109(3):205-9 [14763959.001]
  • [Cites] Anesth Analg. 2004 Apr;98(4):1133-9, table of contents [15041613.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Mar;24(3):291-7 [15091109.001]
  • [Cites] Stroke. 2004 Jun;35(6):1280-3 [15105509.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2698-704 [15184294.001]
  • [Cites] Curr Vasc Pharmacol. 2004 Jan;2(1):13-21 [15320829.001]
  • [Cites] Neurosurgery. 1980 Jan;6(1):1-9 [7354892.001]
  • [Cites] Neurol Res. 1980;2(3-4):253-72 [6111034.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):199-203 [6888700.001]
  • [Cites] Neurol Res. 1984 Mar-Jun;6(1-2):49-53 [6147779.001]
  • [Cites] Arch Neurol. 1986 Jan;43(1):30-3 [3942510.001]
  • [Cites] Neurosurgery. 1986 Jan;18(1):1-6 [3945370.001]
  • [Cites] Stroke. 1987 Nov-Dec;18(6):1061-7 [3686578.001]
  • [Cites] Clin Neurol Neurosurg. 1988;90(1):53-6 [3359734.001]
  • [Cites] Science. 1988 Apr 29;240(4852):622-30 [3283935.001]
  • [Cites] Stroke. 1988 Oct;19(10):1250-6 [3176085.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 May;30(5):309-16 [1699146.001]
  • [Cites] Stroke. 1991 Jul;22(7):854-9 [1830180.001]
  • [Cites] Stroke. 1991 Aug;22(8):971-82 [1866764.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):337-54 [1506880.001]
  • [Cites] N Engl J Med. 1992 Sep 24;327(13):916-20 [1513348.001]
  • [Cites] Clin Neurosurg. 1993;40:40-55 [8111992.001]
  • [Cites] Trends Neurosci. 1994 Dec;17(12):525-30 [7532337.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):137-45 [7709776.001]
  • [Cites] Lancet. 1995 Aug 26;346(8974):575 [7658797.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):668-72; discussion 672-3 [17415203.001]
  • [Cites] Trends Pharmacol Sci. 2007 Jun;28(6):252-6 [17466386.001]
  • [Cites] Neurology. 2007 Aug 21;69(8):766-75 [17709709.001]
  • [Cites] Neurosurgery. 2007 Aug;61(2):255-60; discussion 260-1 [17762737.001]
  • [Cites] Crit Care. 2007;11(4):220 [17705883.001]
  • [Cites] Stroke. 2008 Apr;39(4):1103-8 [18309169.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Jun;28(6):1204-11 [18319732.001]
  • [Cites] Neurosurgery. 2008 Aug;63(2):198-203; discussion 203 [18797348.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Nov;28(11):1761-70 [18628782.001]
  • [Cites] Stroke. 2008 Nov;39(11):3015-21 [18688013.001]
  • [Cites] J Neurosurg. 2008 Dec;109(6):1052-9 [19035719.001]
  • [Cites] Biol Res Nurs. 2009 Jan;10(3):205-12 [19017669.001]
  • [Cites] J Neurosurg. 2009 Mar;110(3):475-81 [19061349.001]
  • [Cites] J Neurosurg. 2009 May;110(5):989-95 [19199499.001]
  • [Cites] Stroke. 2009 Jun;40(6):1963-8 [19359629.001]
  • [Cites] DNA Cell Biol. 2009 Jul;28(7):329-34 [19435422.001]
  • [Cites] Brain. 2009 Jul;132(Pt 7):1866-81 [19420089.001]
  • [Cites] Neuroradiology. 2009 Dec;51(12):813-9 [19623472.001]
  • [Cites] Acta Neurochir (Wien). 2010 Feb;152(2):257-62 [19826759.001]
  • [Cites] Cytokine Growth Factor Rev. 1999 Jun;10(2):119-30 [10743503.001]
  • [Cites] Neurobiol Aging. 2000 Mar-Apr;21(2):245-55 [10867209.001]
  • [Cites] J Investig Med. 2000 Sep;48(5):367-74 [10979242.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Sep;20(9):1360-71 [10994858.001]
  • [Cites] Arch Neurol. 2000 Oct;57(10):1480-4 [11030801.001]
  • [Cites] Crit Care Med. 2001 Jan;29(1):77-9 [11176164.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):534-7 [11254783.001]
  • [Cites] Pharmacogenomics. 2001 Feb;2(1):11-24 [11258193.001]
  • [Cites] Neurosurgery. 2001 May;48(5):1006-10; discussion 1010-1 [11334266.001]
  • [Cites] Stroke. 2001 Aug;32(8):1860-2 [11486117.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Aug;21(8):887-906 [11487724.001]
  • [Cites] Stroke. 2001 May;32(5):1181-4 [11340230.001]
  • [Cites] Acta Neurochir Suppl. 2001;77:7-11 [11563312.001]
  • [Cites] Stroke. 2001 Oct;32(10):2292-8 [11588316.001]
  • [Cites] Pharmacogenetics. 2001 Nov;11(8):719-25 [11692081.001]
  • [Cites] Stroke. 2002 Feb;33(2):548-52 [11823668.001]
  • [Cites] Stroke. 2002 Mar;33(3):782-9 [11872904.001]
  • [Cites] Am J Cardiol. 2000 Mar 15;85(6):710-4 [12000044.001]
  • [Cites] Adv Exp Med Biol. 2002;513:87-113 [12575818.001]
  • (PMID = 20068580.001).
  • [ISSN] 1559-7016
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 106
  • [Other-IDs] NLM/ PMC2949164
  •  go-up   go-down


84. Madden LA, Laden G: Gas bubbles may not be the underlying cause of decompression illness - The at-depth endothelial dysfunction hypothesis. Med Hypotheses; 2009 Apr;72(4):389-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gas bubbles may not be the underlying cause of decompression illness - The at-depth endothelial dysfunction hypothesis.
  • Gas formed in tissues and the circulating blood due to decompression is thought to be a significant factor in the progression of decompression illness (DCI).
  • DCI is a potential problem for a growing population of professional and recreational divers.
  • We hypothesise that these gas bubbles are not the causative agent in progression of DCI, rather an exacerbating factor.
  • Bubbles have the potential to exacerbate the situation on decompression by damaging the vascular endothelium either through ischemia/reperfusion, physical contact with the endothelium or by an increase in shear stress.
  • [MeSH-major] Decompression Sickness / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128890.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antioxidants
  •  go-up   go-down


85. Tamaki H, Kohshi K, Ishitake T, Wong RM: A survey of neurological decompression illness in commercial breath-hold divers (Ama) of Japan. Undersea Hyperb Med; 2010 Jul-Aug;37(4):209-17
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A survey of neurological decompression illness in commercial breath-hold divers (Ama) of Japan.
  • Repetitive breath-hold diving with a deep dive depth, long dive time, and short surface interval predisposes divers to decompression illness, which characteristically manifests as cerebral stroke.
  • [MeSH-major] Diving / adverse effects. Nervous System Diseases / etiology. Occupational Diseases / etiology

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737928.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux Pd, Dilhuydy JM, Fondrinier E, Fourme E, Giard-Lefevre S, Blanc-Onfroy ML, Lemanski C, Mauriac L, Sigal-Zafrani B, Tardivon A, This P, Tunon de Lara C, Kirova Y, Fabre N, Federation of French Cancer Centres (FNCLCC), et le groupe de travail SOR: [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004]. Bull Cancer; 2005 Feb;92(2):155-68
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].
  • [Transliterated title] Recommandations pour la pratique clinique: Standards, Options et Recommandations 2004 pour la prise en charge des carcinomes canalaires in situ du sein (rapport abrégé).
  • The " Standards, Options and Recommendations " (SOR) project, started in 1993, is a collaboration between the Federation of French Cancer Centres (FNCLCC), the 20 French cancer centres, and specialists from French public universities, general hospitals and private clinics.
  • The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients.
  • The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.
  • Objectives : To update the Standards, Options and Recommendations clinical practice guidelines for the management of ductal carcinoma in situ of the breast (DCIS).
  • Results : Clinical guidelines have been defined for the management of diagnosis, treatment, follow-up, and treatment of recurrence of DCIS.
  • The issue of hormone replacement therapy has also been addressed in the context of DCIS.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749645.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline
  • [Publication-country] France
  •  go-up   go-down


87. Bennett MH, Lehm JP, Mitchell SJ, Wasiak J: Recompression and adjunctive therapy for decompression illness: a systematic review of randomized controlled trials. Anesth Analg; 2010 Sep;111(3):757-62
Hazardous Substances Data Bank. HELIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recompression and adjunctive therapy for decompression illness: a systematic review of randomized controlled trials.
  • INTRODUCTION: Decompression illness (DCI) is caused by bubble formation in the blood or tissues after a reduction in ambient pressure.
  • Clinically, DCI may range from a trivial illness to paralysis, loss of consciousness, cardiovascular collapse, and death.
  • Recompression is the universally accepted standard for the treatment of DCI.
  • When recompression is delayed, a number of strategies have been suggested to improve the outcome.
  • We examined the effectiveness and safety of both recompression and adjunctive therapies in the treatment of DCI.
  • In one study, there was no evidence of improved effectiveness with the addition of a nonsteroidal antiinflammatory drug to routine recompression therapy (at 6 weeks: relative risk 1.04, 95% confidence interval [CI]: 0.90-1.20, P = 0.58), but there was a reduction in the number of recompression treatments required when tenoxicam was added (P = 0.01, 95% CI: 0-1).
  • DISCUSSION: Recompression therapy is the standard for treatment of DCI, but there is no RCT evidence.
  • The addition of a nonsteroidal antiinflammatory drug (tenoxicam) or the use of heliox may reduce the number of recompressions required, but neither improves the odds of recovery.
  • [MeSH-major] Decompression Sickness / therapy
  • [MeSH-minor] Air Pressure. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Helium / therapeutic use. Humans. Oxygen Inhalation Therapy. Piroxicam / analogs & derivatives. Piroxicam / therapeutic use. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anesth Analg. 2010 Sep;111(3):589-90 [20733161.001]
  • (PMID = 20332190.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; 206GF3GB41 / Helium; 59804-37-4 / tenoxicam
  • [Number-of-references] 28
  •  go-up   go-down


88. Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R: A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol Res; 2008 Nov;30(9):893-7
Hazardous Substances Data Bank. SIMVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality.
  • OBJECTIVE: To analyse the effect of the implementation of statin and magnesium treatment on delayed cerebral ischemia (DCI) and 14 day mortality in patients with subarachnoid hemorrhage (SAH).
  • RESULTS: Eighteen percent (n=5) of patients receiving statin and magnesium treatment developed a DCI whereas 24% (n=5) in the statin group and 16% (n=8) in the control group had DCI.
  • A higher incidence for DCI was found in the statin group, whereas patients without statin and magnesium tended to have less often DCI.
  • [MeSH-minor] Anticholesteremic Agents / adverse effects. Anticholesteremic Agents / therapeutic use. Brain Ischemia / epidemiology. Brain Ischemia / etiology. Brain Ischemia / mortality. Case-Control Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691455.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; AGG2FN16EV / Simvastatin; I38ZP9992A / Magnesium
  •  go-up   go-down


89. Kohshi K, Wong RM, Higashi T, Katoh T, Mano Y: [Acute decompression illness following hyperbaric exposure: clinical features of central nervous system involvement]. J UOEH; 2005 Sep 1;27(3):249-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute decompression illness following hyperbaric exposure: clinical features of central nervous system involvement].
  • Decompression illness (DCI) is a general term encompassing all pathological changes secondary to reduction of environmental pressure.
  • This condition has two forms: decompression sickness (DCS) and arterial gas embolism (AGE) secondary to pulmonary barotrauma.
  • Cerebral and spinal injuries have been symptomatically classified into AGE and DCS.
  • Brain scans of patients with AGE or DCS showed multiple cerebral infarctions in the terminal and/or border zones of the cerebral arteries.
  • Despite established treatments for neurological DCI (both AGE and DCS), it is unclear whether US Navy treatment Table 6 is preferable to standard hyperbaric oxygen therapy such as 2.4 atmospheres pressure for 90 minutes.
  • Japanese laws and regulations have peculiarities that permit air diving to 90 meters depth, but with explicit prohibition of the use of oxygen for decompression, albeit a limited use of mixed gas is permissible.
  • [MeSH-major] Brain / physiopathology. Decompression Sickness / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180512.001).
  • [ISSN] 0387-821X
  • [Journal-full-title] Journal of UOEH
  • [ISO-abbreviation] J. UOEH
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


90. Padilla W, Newton HB, Barbosa S: Weber's syndrome and sixth nerve palsy secondary to decompression illness: a case report. Undersea Hyperb Med; 2005 Mar-Apr;32(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weber's syndrome and sixth nerve palsy secondary to decompression illness: a case report.
  • We describe the first case of Weber's Syndrome to present as a manifestation of decompression illness in a recreational scuba diver.
  • The patient was a 55 year-old male with a past medical history of a pulmonary cyst, in whom symptoms developed after a multilevel drift dive to a depth of 89 feet for 53 minutes, exceeding no-decompression limits.
  • The mechanism of injury remains unclear, but may involve aspects of both air gas embolism and decompression sickness.
  • [MeSH-major] Abducens Nerve Diseases / etiology. Decompression Sickness / complications. Ophthalmoplegia / etiology
  • [MeSH-minor] Ataxia / etiology. Cysts / complications. Diving / adverse effects. Dizziness / etiology. Humans. Lung Diseases / complications. Male. Middle Aged. Nausea / etiology. Sensation Disorders / etiology. Syndrome

  • Genetic Alliance. consumer health - Sixth nerve palsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15926301.001).
  • [ISSN] 1066-2936
  • [Journal-full-title] Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • [ISO-abbreviation] Undersea Hyperb Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


91. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YB: Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke; 2010 Oct;41(10):2391-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group.
  • BACKGROUND AND PURPOSE: In clinical trials and observational studies there is considerable inconsistency in the use of definitions to describe delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage.
  • A major cause for this inconsistency is the combining of radiographic evidence of vasospasm with clinical features of cerebral ischemia, although multiple factors may contribute to DCI.
  • METHODS: An international ad hoc panel of experts involved in subarachnoid hemorrhage research developed and proposed a definition of DCI to be used as an outcome measure in clinical trials and observational studies.
  • RESULTS: It is proposed that in observational studies and clinical trials aiming to investigate strategies to prevent DCI, the 2 main outcome measures should be:.
  • (1) cerebral infarction identified on CT or MRI or proven at autopsy, after exclusion of procedure-related infarctions; and (2) functional outcome.
  • Secondary outcome measure should be clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration.
  • Vasospasm on angiography or transcranial Doppler can also be used as an outcome measure to investigate proof of concept but should be interpreted in conjunction with DCI or functional outcome.
  • CONCLUSIONS: The proposed measures reflect the most relevant morphological and clinical features of DCI without regard to pathogenesis to be used as an outcome measure in clinical trials and observational studies.
  • [MeSH-major] Brain Ischemia / etiology. Subarachnoid Hemorrhage / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20798370.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501444; United States / NINDS NIH HHS / NS / P50 NS05597701A2; United States / NINDS NIH HHS / NS / P50NS035966
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Kot J, Sićko Z, Michałkiewicz M, Lizak E, Góralczyk P: Recompression treatment for decompression illness: 5-year report (2003-2007) from National Centre for Hyperbaric Medicine in Poland. Int Marit Health; 2008;59(1-4):69-80
MedlinePlus Health Information. consumer health - Traveler's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recompression treatment for decompression illness: 5-year report (2003-2007) from National Centre for Hyperbaric Medicine in Poland.
  • All of them were treated with recompression treatment in the National Centre for Hyperbaric Medicine in Gdynia which has capability to treat any patient with decompression illness using all currently available recompression schedules with any breathing mixtures including oxygen, nitrox, heliox or trimix.
  • The time interval between surfacing and first occurrence of symptoms was significantly lower in the group of patients with neurological decompression sickness or arterial gas embolism (median 0.2 hours) than in the group of patients with other types of decompression sickness (median 2.0 hours).
  • In 2 cases initial diagnosis of decompression sickness type I was rejected after initial recompression treatment and careful re-evaluation of diving profiles, risk factors and reported symptoms.
  • [MeSH-major] Decompression Sickness / diagnosis. Decompression Sickness / therapy. Diving / injuries. Oxygen Inhalation Therapy / methods. Travel
  • [MeSH-minor] Academic Medical Centers. Adult. Embolism, Air / diagnosis. Embolism, Air / therapy. Humans. Middle Aged. Poland. Pulmonary Edema / diagnosis. Pulmonary Edema / therapy. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oxygen Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227740.001).
  • [ISSN] 1641-9251
  • [Journal-full-title] International maritime health
  • [ISO-abbreviation] Int Marit Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


93. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB: Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke; 2010 Jan;41(1):e47-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
  • BACKGROUND AND PURPOSE: A recent meta-analysis investigating the efficacy of statin treatment in patients with aneurysmal subarachnoid hemorrhage reported a reduced incidence of vasospasm, delayed cerebral ischemia, and mortality in statin-treated patients.
  • We present the results of a new systematic review, which differs from the previous systematic review in its methodology, and by inclusion of the results of a fourth randomized, placebo-controlled trial.
  • Summary of Review- All randomized, placebo-controlled trials investigating the effect of statins on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage were included.
  • Outcomes were the number of patients with transcranial Doppler vasospasm, delayed cerebral ischemia, poor outcome, and mortality during follow-up.
  • No statistically significant effect was observed on transcranial Doppler vasospasm (pooled risk ratio, 0.99 [95% CI, 0.66 to 1.48]), delayed cerebral ischemia (pooled risk ratio, 0.57 [95% CI, 0.29 to 1.13]), poor outcome (pooled risk ratio, 0.92 [95% CI, 0.68 to 1.24]), or mortality (pooled risk ratio, 0.37 [95% CI, 0.13 to 1.10]).
  • CONCLUSIONS: The results of the present systematic review do not lend statistically significant support to the finding of a beneficial effect of statins in patients with aneurysmal subarachnoid hemorrhage as reported in a previous meta-analysis.
  • [MeSH-major] Brain Ischemia / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Subarachnoid Hemorrhage / drug therapy. Vasospasm, Intracranial / drug therapy


94. Paglia G, D'Apolito O, Corso G: Precursor ion scan profiles of acylcarnitines by atmospheric pressure thermal desorption chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom; 2008 Dec;22(23):3809-15
Hazardous Substances Data Bank. L-CARNITINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor ion scan profiles of acylcarnitines by atmospheric pressure thermal desorption chemical ionization tandem mass spectrometry.
  • The fatty acyl esters of L-carnitine (acylcarnitines) are useful biomarkers for the diagnosis of some inborn errors of metabolism analyzed by liquid chromatography/tandem mass spectrometry.
  • In this study the acylcarnitines were analyzed by atmospheric pressure thermal desorption chemical ionization using a commercial tandem mass spectrometer (APTDCI-MS/MS).
  • During desorption/ionization step the temperature induces the degradation of acylcarnitines; nevertheless, the common fragment to all acylcarnitines [MH-59](+) is useful for analyzing their profile.
  • The specificity was evaluated by comparing product ion spectra and the precursor ion spectra of 85 m/z of acylcarnitines obtained by the APTDCI method and by electrospray ionization flow injection analysis (ESI-FIA).
  • The method enables analysis of biological samples and recognition of some acylcarnitines that are diagnostic markers of inherited metabolic diseases.
  • The intrinsic high-throughput analysis of the ambient desorption ionization methods offers a new opportunity either for its potential application in clinical chemistry and for the expanded screening of some inborn errors of metabolism.
  • [MeSH-major] Carnitine / analogs & derivatives. Spectrometry, Mass, Electrospray Ionization / methods. Tandem Mass Spectrometry / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980266.001).
  • [ISSN] 0951-4198
  • [Journal-full-title] Rapid communications in mass spectrometry : RCM
  • [ISO-abbreviation] Rapid Commun. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / acylcarnitine; S7UI8SM58A / Carnitine
  •  go-up   go-down


95. van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E: Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol; 2009 Oct;62(10):926-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
  • AIMS: Ductal carcinoma in situ (DCIS) is an established late precursor of sporadic invasive breast cancer and to a large extent parallels its invasive counterpart with respect to molecular changes and immunophenotype.
  • Invasive breast cancers in germline BRCA1 and BRCA2 mutation carriers have a distinct "basal" and "luminal" immunophenotype, respectively, but the immunophenotype of their precursor lesions has hardly been studied, and this was the aim of this study.
  • METHODS: DCIS lesions of 25 proven BRCA1 and 9 proven BRCA2 germline mutation carriers and their 22 and 6, respectively, accompanying invasive lesions were stained by immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER)2/neu, cytokeratin (CK)5/6, CK14, epidermal growth factor receptor (EGFR) and Ki67.
  • RESULTS: DCIS lesions in BRCA1 mutation carriers were mostly of the basal molecular type with low ER/PR/HER2 expression, while they frequently expressed CK5/6, CK14 and EGFR, and were mostly grade 3 and highly proliferative.
  • DCIS lesions in BRCA2 mutation carriers were mostly of luminal molecular type with frequent expression of ER/PR, and infrequent expression of CK5/6, CK14 and EGFR, and they were mostly grade 3 and showed low proliferation.
  • In BRCA1 and BRCA2 mutation carriers there was a high concordance between DCIS lesions and their concomitant invasive counterpart with regard to expression of individual markers as well as "molecular" subtype.
  • CONCLUSIONS: Although the number of cases studied was low, DCIS lesions in BRCA1 and BRCA2 mutations carriers are usually of the basal and luminal molecular type, respectively, similar to their accompanying invasive cancers, thereby providing evidence that DCIS is a direct precursor lesion in these hereditary predisposed patients.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Female. Humans. Immunophenotyping. Neoplasm Proteins / metabolism


96. Gill JK, Maskarinec G, Pagano I, Kolonel LN: The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res; 2006;8(3):R30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort.
  • INTRODUCTION: It is well established that women with high mammographic density are at greater risk for breast cancer than are women with low breast density.
  • However, little research has been done on mammographic density and ductal carcinoma in situ (DCIS) of the breast, which is thought to be a precursor lesion to some invasive breast cancers.
  • METHOD: We conducted a nested case-control study within the Multiethnic Cohort, and compared the mammographic densities of 482 patients with invasive breast cancer and 119 with breast DCIS cases versus those of 667 cancer-free control subjects.
  • A reader blinded to disease status performed computer-assisted density assessment.
  • RESULTS: Mammographic density was associated with invasive breast cancer and breast DCIS.
  • For the highest category of percentage breast density (> or = 50%) as compared with the lowest (< 10%), the OR was 3.58 (95% CI 2.26-5.66) for invasive breast cancer and 2.86 (1.38-5.94) for breast DCIS.
  • Similarly, for the highest category of dense area (> or = 45 cm2) as compared with the lowest (< 15 cm2), the OR was 2.92 (95% CI 2.01-4.25) for invasive breast cancer and 2.59 (1.39-4.82) for breast DCIS.
  • Trend tests were significant for invasive breast cancer (P for trend < 0.0001) and breast DCIS (P for trend < 0.001) for both percentage density and dense area.
  • CONCLUSION: The similar strength of association for mammographic density with breast DCIS and invasive breast cancer supports the hypothesis that both diseases may have a common etiology.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2000;10(1):157-61 [10663736.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703 [10919740.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):153-61 [11097091.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1811-7 [11734598.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):332-8 [12692108.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):906-20 [15199110.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1467-72 [15467036.001]
  • [Cites] JAMA. 1983 Jan 28;249(4):483-7 [6848848.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2833-8 [2025849.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 5;84(15):1170-9 [1635085.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):670-5 [7752271.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1622-9 [7563205.001]
  • [Cites] JAMA. 1996 Mar 27;275(12):913-8 [8598618.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1298-305 [8630296.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1197-200 [8630897.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):961-5 [8959317.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 1;89(1):76-82 [8978410.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):330-2 [9663590.001]
  • [Cites] JAMA. 1999 Jun 9;281(22):2091-7 [10367819.001]
  • [Cites] Phys Med Biol. 1994 Oct;39(10):1629-38 [15551535.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65 [15601642.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):323-7 [15540225.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1052-9 [15894652.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R605-8 [16168104.001]
  • [Cites] Am J Epidemiol. 2005 Oct 15;162(8):743-52 [16150892.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):798-808 [16198986.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • (PMID = 16796758.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA090956; United States / NCI NIH HHS / CA / R25 CA 90956; United States / NCI NIH HHS / CA / R01 CA 85265; United States / NCI NIH HHS / CA / R01 CA085265; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CA / R37 CA 54281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1557731
  •  go-up   go-down


97. Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S: Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol; 2008 Mar 10;26(8):1247-52
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.
  • PURPOSE: Evaluate the effects of radiotherapy after sector resection for ductal carcinoma in situ of the breast (DCIS) in patient groups as defined by age, size of the lesion, focality, completeness of excision and mode of detection.
  • PATIENTS AND METHODS: A total of 1,067 women in Sweden were randomly assigned to either postoperative radiotherapy (RT) or control from 1987 to 1999, and 1,046 were followed for a mean of 8 years.
  • The main outcome was new ipsilateral breast cancer events and distant metastasis-free survival analyzed according to intention to treat.
  • We caution that the age effect was seen in a subgroup analysis.
  • Further search with conventional clinical variables for a low risk group that does not need RT does not seem fruitful.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Aged. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Female. Humans. Middle Aged. Postoperative Period. Risk Reduction Behavior. Survival Rate. Sweden. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250350.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Krishnan C, Longacre TA: Ductal carcinoma in situ of the breast with osteoclast-like giant cells. Hum Pathol; 2006 Mar;37(3):369-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal carcinoma in situ of the breast with osteoclast-like giant cells.
  • Mammary carcinoma with multinucleated osteoclast-like giant cells (OGCs) is a rare, distinctive variant of breast carcinoma.
  • To date, all of these instances have been described as part of an invasive carcinoma.
  • Here, we report a case of ductal carcinoma in situ of the breast with numerous admixed OGCs present within gland lumens without an associated invasive component.
  • Similar to invasive carcinomas with OGCs, both the in situ carcinoma and the OGCs exhibited overexpression for vascular endothelial growth factor.
  • This case expands the spectrum of tumors associated with OGCs and provides further evidence for the possible role of vascular endothelial growth factor in the stromal-epithelial interactions of in situ mammary carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Giant Cells / pathology. Osteoclasts / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613333.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


99. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O, breast cancer study group of the Institut Curie: Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res; 2008 Apr 1;14(7):1956-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
  • PURPOSE: To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS).
  • EXPERIMENTAL DESIGN: We did a combined phenotypic and genomic analysis of a series of 57 DCIS integrated with gene expression profile analysis for 26 of the 57 cases.
  • RESULTS: Thirty-two DCIS exhibited a luminal phenotype; 21 were ERBB2 positive, and 4 were ERBB2/estrogen receptor (ER) negative with 1 harboring a bona fide basal-like phenotype.
  • Based on a CGH analysis, genomic types were identified in this series of DCIS with the 1q gain/16q loss combination observed in 3 luminal DCIS, the mixed amplifier pattern including all ERBB2, 12 luminal and 2 ERBB2(-)/ER(-) DCIS, and the complex copy number alteration profile encompassing 14 luminal and 1 ERBB2(-)/ER(-) DCIS.
  • Unsupervised analysis of gene expression profiles of 26 of the 57 DCIS showed that luminal and ERBB2-amplified, ER-negative cases clustered separately.
  • Strikingly, amplicons but also low copy number changes especially on 1q, 8q, and 16q in DCIS regulated the expression of a subset of genes in a very similar way to that recently described in invasive ductal carcinomas.
  • CONCLUSIONS: These combined approaches show that the molecular heterogeneity of breast ductal carcinomas exists already in in situ lesions and further indicate that DCIS and invasive ductal carcinomas share genomic alterations with a similar effect on gene expression profile.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Gene Expression Profiling. Genomics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381933.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Investigator] Asselain B; Aurias A; Barillot E; Bollet M; Campana F; Cottu P; de Cremoux P; Diéras V; Mignot L; Pierga JY; Poupon MF; Stoppa-Lyonnet D; Tardivon A; Thibault F; This P
  •  go-up   go-down


100. Zhou L, Wang Y, Song X, Du JW, Pei F, Huang LP, Wang WY, Liu ZB, Pan RQ: [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast]. Zhonghua Yi Xue Za Zhi; 2005 Nov 16;85(43):3035-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
  • OBJECTIVE: To investigate the clinicopathologic features of and appropriate treatment of ductal carcinoma in situ of the breast (DCIS).
  • METHODS: The clinical and pathologic data of 41 cases of DCIS, aged 52.7 (30-82), 15 of which were diagnosed as with ductal carcinoma in situ with microinvasion (DCIS-MI) and of which 18 were in the Van Nuys grade I, 13 in the grade II, and 10 in the grade III, were collected and analyzed.
  • There was no significant difference in the expression of the biologic markers between the patients with DCIS and those with DCIS-MI.
  • CONCLUSION: The Van Nuys histologic classification accords with the requirement of clinical treatment and prognosis.
  • The patients with DCIS should undergo individualized treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324401.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down






Advertisement